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Abstract 
Objectives: Catecholamine-mediated effects driven by elevated adrenergic 
signaling are known to increase tumor growth and metastasis by direct effects on 
tumor cells. However, knowledge of effects of adrenergic signaling on other cells 
such as cancer-associated fibroblasts (CAFs) within the tumor microenvironment 
is limited. We hypothesize that adrenergic signaling and norepinephrine can 
accelerate the induction of CAF-phenotype to promote inflammation and 
metastasis. 
Methods: Ingenuity Pathway Analysis and NetWalker were used to assess gene 
expression data from patients with known CESD (Center for Epidemiological 
Studies-Depression)-score alongside microdissected CAFs from primary ovarian 
cancer.  Tumor samples from mice exposed to daily restraint-stress or non-
stressed controls were assessed for alpha-smooth muscle actin (a-SMA) 
expression. Normal fibroblasts (NoF 151) were treated with conditioned media 
from non-treated and norepinephrine (NE) treated Skov3 and HeyA8 cells and 
analyzed for induction of CAF-phenotype by a-SMA expression. Gene and 
protein expression of cytokines and changes in migratory potential of fibroblasts 
were assessed.  
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Results: Among the significantly upregulated genes (fold-change >2) in patients 
with known CESD-score, 34 genes overlapped with microdissected CAF data. 
Among them are several networks involved in extracellular matrix (ECM) and 
inflammatory response. Restraint stress was associated with significantly 
increased levels of α -SMA, a marker for CAFs by both intensity and distribution 
in Skov3, HeyA8 and ID8 tumors. These increases in α-SMA were abrogated 
when mice were treated with broad beta-blocker propranolol during restraint 
stress in HeyA8 and Skov3 model. Further bioinformatics analysis of these 
datasets combined with gene array data from conditioned normal fibroblasts 
showed collagens are the most important biological downstream effectors for the 
adrenergic induced CAF phenotype. Consistent with the bioinformatics analyses, 
there was increased collagen (assessed by Trichrome stain) in the tumors from 
restraint-stress animals, and these were abrogated by propranolol treatment. 
Upstream bioinformatics analysis of CAF mediators showed cancer-cell derived 
INHBA (inhibin beta A, a member of the TGF-b family) can mediate the induction 
of CAF-phenotype upon adrenergic stimulation. Silencing INHBA in tumor cells 
decreased stress-induced tumor growth in Skov3 orthotropic model as well as 
decreasing levels of CAFs and collagen in tumors. 
Conclusion: Sustained adrenergic stimulation results in significant increases in 
the CAF content in-vivo and accelerates conversion of normal fibroblasts to 
CAFs in vitro (fold change-2 fold, p<0.05). Adrenergic-mediated changes in CAF 
phenotype can increase production of pro-inflammatory cytokines and promote 
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inflammation. This project provides a better understanding of the adrenergic 
influences on the stroma within the tumor microenvironment. 
3  
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1.1 Chronic Stress 
1.1.1 History of the “General Adaptation Response” 
 A stress response is an evolutionarily conserved and non-specific adaptation 
mechanism that is triggered during distress or threats. Hans Selye pioneered the 
work on stress in 1930s [1, 2]. In his early studies, he noticed common symptoms 
such as loss-of appetite, muscle mass and anhedonia in patients who came to 
hospitals with very diverse ailments such as burns, end-stage cancer, infectious 
disease [2]. As a researcher who was studying the response of a new hormone 
in rats, Han Selye discovered what he defined as the triad of responses: 
enlarged adrenal glands, involuted lymphatic organs and severe bleeding in the 
duodenum and stomach [3]. He attributed this to the ‘General Adaptation 
Syndrome’ [4-6]. He further explained that this response consisted of 3 phases: 
alarm reaction, resistance and exhaustion. In the first phase, which is the alarm 
reaction, the body prepares to the threat by increasing levels of corticoids in the 
bloodstream and the adrenal glands are depleted of lipids. As this phase 
prolongs, the body enters the phase of resistance where there is an increased 
supply of corticoids and lipids in the adrenal glands accompanied by 
hemoconcentration and anabolism. The final stage, Hans Selye called the stage 
of exhaustion where the body is can no longer fight the severe stress [7]. The 
fundamental flaw with Selye’s experiments was that he hypothesized that stress 
hormones run out after chronic episodes of stress, but subsequent studies on 
stress responses showed that levels remain elevated and have several biological 
implications. 
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1.1.2 Stress Response 
Chronic stress is defined as a nonspecific response of the body to any long 
standing demand. The ‘demands’ also known as stressors can be a physical or 
an emotional exertion, but the biological manifestation will be the same [8]. 
Colloquially called ‘the fight-or-flight’ response, this refers to an acute response 
that prepares the body to perceive and react to a threat. Such a response is both 
necessary and indispensable to animals. Acute stress responses are what 
enable a prey to run away form a predator, fight impending danger, and veer 
away from an incoming car [9]. These examples manifest acute stress, which is 
often short lived, transient and beneficial to the organism. In contrast, American 
Psychological Association defines chronic stress in individuals as a “cascade of 
negative emotions such as anxiety, anger and distress that also leads to 
predictable biochemical, physiological, and behavioral changes”[8].  
1.1.3 Biology of the stress response 
The normal biochemical manifestation of a stress response is the same 
irrespective of the source of stress. In response to a perceived threat, the 
hypothalamus is activated. There are 2 arms to the stress response: 
sympathomedullary pathway (SAM) or hypothalamic pituitary axis (HPA) that 
leads to production of norepinephrine (NE) and cortisol respectively (figure 1). In 
SAM, hypothalamic activation of the adrenal medulla results in the secretion of 
epinephrine. Adrenal medulla is part of the autonomic nervous system and 
chromaffin cells in the medulla are the primary source of catecholamines 
epinephrine and norepinephrine in the body. At times of high sympathetic nerve 
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activation, the amount of norepinephrine entering the blood increases 
dramatically. In HPA axis, hypothalamus activates the pituitary gland to produce 
adrenocorticotropic hormone (ACTH). ACTH then stimulates the adrenal cortex 
to produce corticosteroids such as cortisol that enters the bloodstream.   
 
Figure 1: Stress Response. [10] (M.H. Antoni, S.K. Lutgendorf, S.W. Cole, F.S. 
Dhabhar, S.E. Sephton, P.G. McDonald, M. Stefanek, A.K. Sood, The influence 
of bio-behavioural factors on tumour biology: pathways and mechanisms, Nat 
Rev Cancer, 6 (2006) 240-248.) Nature Reviews Cancer by NATURE 
PUBLISHING GROUP. Reproduced with permission of NATURE PUBLISHING 
GROUP in the format Republish in a thesis/dissertation via Copyright Clearance 
Center.  
In patients with cancer, both cortisol and norepinephrine levels are elevated with 
different biological functions. Lutgendorf et al studied NE levels in ovarian cancer 
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patients in both blood plasma and tumors [11]. In 68 ovarian cancer patients, 
tumor samples were collected and a pathologist confirmed for ovarian carcinoma 
histology were confirmed. Tumor samples were obtained from 20 patients, and 
plasma catecholamines were available for 53 patients (22 had ascites which is 
the fluid accumulation in the peritoneal cavity commonly seen in ovarian cancer 
patients). Patients were also assessed for biobehavioral profiles using CESD 
(Center for Epidemiological Studies-Depression) scores and assessed as high 
risk (score>=16) or low risk (score<15). Tumor samples and plasma were also 
analyzed for NE levels using HPLC (high performance liquid chromatography). 
Low risk patients showed minimal intra-tumor NE (all samples had less than 
<0.1 pg/mg tissue assay), whereas tissues from high-risk patients showed 
significantly greater NE concentrations with a significant increase in tumoral NE 
with a mean = 19.5 ± 6.9 pg/mg tissue (figure 2). There were no significant 
differences in plasma collected from the same patients 2 hours prior to resection 
surgery. The authors of the study also point that the differences between tumor 
and plasma levels of NE in the groups that catecholamines in peripheral 
circulation are likely not responsible for the bulk of the intratumoral 
catecholamine levels. Unpublished data in our lab has shown that chronic 
adrenergic signaling can lead to neoinnervation driven by BDNF produced by 
tumor cells. Peripheral nerves infiltrating the tumor can produce NE in the tumor, 
and the low acidic pH of the tumor microenvironment also helps in increasing the 
stability of NE within the tumor. Removal of the adrenal glands did not affect 
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tumoral NE levels, indicating that systemic sources of NE do not drive tumoral 
NE levels. 
 
Figure 2: NE levels in ovarian tumors and circulating blood [11] (S.K. Lutgendorf, 
K. DeGeest, L. Dahmoush, D. Farley, F. Penedo, D. Bender, M. Goodheart, T.E. 
Buekers, L. Mendez, G. Krueger, L. Clevenger, D.M. Lubaroff, A.K. Sood, S.W. 
Cole, Social isolation is associated with elevated tumor norepinephrine in ovarian 
carcinoma patients, Brain Behav Immun, 25 (2011) 250-255.) Brain, behavior, 
and immunity by Psychoneuroimmunology Research Society Reproduced with 
permission of ACADEMIC PRESS in the format Thesis/Dissertation via Copyright 
Clearance Center. Order License 4081680368687 
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The primary reason to have a stress response was to be a protective response to 
a perceived or imminent threat. At the end of the stressful experience, the body 
gets back to normal by making biobehavioral or biochemical changes. This 
process is commonly referred to as allostasis [12]. Bruce McEwen in his seminal 
work on neurophysiology of stress, defined the term allostatic load as the impact 
on the body as it forced to adapt to adverse situation, either psychological or 
physical. He included that this can be attributed to either too much stress, or 
inability of the stress hormones to turn off after the stressor has passed. 
He explained there are 4 types of allostatic loads commonly seen (figure 3). In a 
normal response, upon removal of stressor or after the perturbation has passed, 
the body enters a recovery state and returns to normal (top panel). In abnormal 
states, there could be a repeated hit or insufficient response. If a person is 
subject to repeated stressors over a long period of time, the levels of cortisol can 
stay elevated exacerbating the chronic effects of stress. In some individuals, 
there may be a lack of adaptation that prevents allostasis (middle panels). In 
some cases, there was an insufficient in the body’s ability to produce appropriate 
responses. A prolonged response occurs when the signals indicated to stop the 
stress response are not triggered in a timely manner (bottom panel left). In 
general, catecholamines increase proinflammatory cytokines viaADRB2 receptor, 
whereas glucocorticoids inhibit production. An inadequate response is generated 
as shown (bottom panel right) when there is insufficient production of 
glucocorticoids during a stress response. This results in prolonged elevated 
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levels of proinflammatory cytokines (Nf-kappaB mediated cytokines) that cannot 
be sufficiently inhibited by low levels of glucocorticoids.  
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Figure 3: Allostatic load [13] (B.S. McEwen, Allostasis and allostatic load: 
implications for neuropsychopharmacology, Neuropsychopharmacology, 22 
(2000) 108-124.) (Neuropsychopharmacology : official publication of the 23  
  
American College of Neuropsychopharmacology by AMERICAN COLLEGE OF 
NEUROPSYCHOPHARMACOLOGY Reproduced with permission of NATURE 
PUBLISHING GROUP in the format Republish in a thesis/dissertation via 
Copyright Clearance Center.  
1.2 Acute v. chronic stress 
In a typical stress response, as shown in figure 4, presence of a stressor is first 
accompanied by increased production of catecholamines within first 30 min [14, 
15]. The catecholaminergic spike provides the rapid response needed to counter 
the stress by increasing via ADRB heart rate, alertness, reducing peripheral 
vision. The glucocorticoids spike an hour after the initial stressor. The role of 
glucocorticoids such as cortisol is to consolidate and terminate the stress 
reactions, mobilize energy resources required for this purpose and facilitate 
recovery. The long term genomic effect of GCs in the brain is to promote memory 
storage in preparation for future events. Catecholamines and GCs are the most 
important molecules produced in the stress response, and the following sections 
describe common signaling mechanisms and effector molecules attributed to 
both signaling pathways. 
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Figure 4: Stress Response and Time [14] (E.J. Hermans, M.J.A.G. Henckens, M. 
Joels, G. Fernandez, Dynamic adaptation of large-scale brain networks in 
response to acute stressors, Trends Neurosci, 37 (2014) 304-314.) Trends in 
neurosciences by ELSEVIER LTD.. Reproduced with permission of ELSEVIER 
LTD. in the format Thesis/Dissertation via Copyright Clearance Center. Order 
License Id: 4081680370430 
1.2.1 Differences between catecholamines and corticosteroids 
Catecholamines such as norepinephrine and corticosteroids such as cortisol 
have different functions during the typical stress response. Sympathetic nervous 
system is activated, accompanied by increased heart rate supplying blood to 
muscles and other organs, increased mobilization of energy, decreased digestion 
and increased breathing to maximize oxygen intake as the body prepares for the 
threat. Cortisol stimulates gluconeogenesis thereby providing a steady source of 
energy during the stress response. In addition, cortisol very potently decreases 
immune function by blocking release of inflammatory molecules and also greatly 
diminishes wound-healing capacity.  
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1.2.2 Adrenergic signaling 
Catecholamine signaling in cells occurs via adrenergic receptors, which are all 
intronless 7-transmembrane G-protein coupled receptors. Epinephrine and 
norepinephrine signal via ADRA and ADRB receptors respectively. There are 5 
alpha-adrenergic (ADRA) receptors ADRA1a, ADRA1b, ADRA2a, ADRA2b and 
ADRA2c, and 3 beta-adrenergic receptors (ADRB) ADRB1, ADRB2 and ADRB3. 
These receptors differ in the G-protein that it is associated with as well as their 
tissue distribution. G proteins are guanosine-binding messengers downstream of 
adrenergic receptors, and can be coupled to cAMP signaling (stimulatory (Gas), 
inhibitor (Gi)) or coupled to phospholipase C (Gq). Alpha adrenergic receptors 
are vasoconstrictive and play an important role in smooth muscle contraction 
ADRA1 associated with Gq subunit that is vital for PLC signaling and smooth 
muscle contraction. In heart, it activates a phosphatidylinositol-calcium second 
messenger system and is important for ERK-signaling. ADRA2 subtypes are 
coupled with Gi subunit that is the inhibitory and decreases both levels of cAMP 
and neurotransmitter release. This in turn decreased smooth muscle contraction.  
26  
  
 
Figure 5: Beta-adrenergic signaling [16] (S.W. Cole, A.K. Sood, Molecular 
Pathways: Beta-Adrenergic Signaling in Cancer, Clin Cancer Res, 18 (2012) 
1201-1206.) Clinical cancer research by American Association for Cancer 
Research ; HighWire Press Reproduced with permission of AMERICAN 
ASSOCIATION FOR CANCER RESEARCH in the format Thesis/Dissertation via 
Copyright Clearance Center. Order License ID: 4081680372059 
ADRBs are all primarily coupled to Gs or stimulatory G-protein subunit (figure 5). 
Upon activation of receptor by norepinephrine, downstream signaling can 
activate several pathways in several discreet cell types, and due to their clinical 
importance, several agonists and antagonists for ADRBs have been identified 
and studied extensively (Table 1). ADRB1 is coupled to Gas, ADRB2 to both Gas 
and Gi and ADRB3 is coupled to Gi/nitric oxide pathway. Coupling to Gs 
increases levels of cAMP and binds the regulatory subunit of PKA and the 
activated catalytic subunit is released. PKA can phosphorylate serine and 
threonine proteins on downstream effectors that have the PKA-specific motif 27  
  
(Arg-Arg-any amino acid-Ser/Thr-hydrophobic amino acid) [16]. One of the most 
important of this is phosphorylation of serine on CREB/ATF (cAMP Response 
Element Binding Protein/Activating Transcription Factor). Genome-wide 
transcription analysis identified 10,447 full CREs and 740,390 half CREs sites in 
the human genome with >4,000 sites on the genome where CREB proteins binds 
[17]. Some of the targets of the transcription factors include important genes 
related to transcription factor activation, cell metabolism, secretory factors and 
cell cycle. To a smaller extent, downstream activation can also activate Nf-kB, an 
important factor in promoting inflammation.  
Type Potency 
(antagonist) 
Tissue  
Distribution 
Characteristics 
ß1 ISO > EPI = 
NE (Practolol, 
ICI 89,406) 
Heart, lung, adrenal 
cortex, adipocyte 
Cardiovascular 
signalling, lipolysis 
ß2 ISO > EPI > 
NE 
(Butoxamine, 
ICI 118,551) 
WBC, NK cells, lung, 
bone marrow, appendix 
Bronchodilation, fight or 
flight response, 
glycogenolysis, insulin 
secretion 
ß3 ISO > EPI 
(BRL-37344, 
Pindolol) 
Salivary gland, omentum, 
thyroid, gall bladder 
Lipolysis, thermogenesis 
Table 1: Beta adrenergic receptor: functions, tissue distribution and chemical 
modulators  
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1.2.3 Glucocorticoid signaling 
Cortisol is the active glucocorticoid that is formed by corticosterone by HSD11b1 
(11β-Hydroxysteroid dehydrogenase type 1) enzyme (figure 6) [18, 19]. 
Glucocorticoid receptor (GR) is the nuclear receptor with three domains an N-
terminal transactivation domain, a DNA-binding domain and a C-terminal ligand 
binding domain. The DNA-binding domain recognizes a DNA sequences called 
as GR- responsive element. GR is inactive and in cytoplasm bound to various 
factors but can be activated in the presence of cortisol. Glucocorticoids regulate 
gene expression in three different ways: the first is to bind directly to DNA the 
second one is to co-activate with other transcription factors bound to DNA and 
third is by alteration of kinases. While association of GR to members of STAT 
family of proteins enhance transcription, association of GR with Nf-KB decreased 
their activity. Glucocorticoids are well studied in their modulation of inflammatory 
pathways, specifically those related to Nf-kB. Reduced Nf-kB activity also results 
in decreased transcription of IL-1b and osteocalcin. Glucocorticoids have potent 
anti-inflammatory actions and exacerbate several diseases including 
osteoporosis, glaucoma, cardiovascular and psychiatric diseases. The same anti-
inflammatory effects of GCs are also used to treat ailments driven by an 
inflammatory response such as rheumatoid arthritis, eczema, asthma and 
psoriasis [19-22]. Glucocorticoids were the first immunosuppressive drugs used 
in organ transplant patients due to their anti-inflammatory and 
immunosuppressive effects on several immune cells. GCs prevent dendritic cell 
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maturation, suppress migration of neutrophils and have moderate activity on both 
T and B cells [23-25].  
 
Figure 6: Glucocorticoid Signaling [18] (R.H. Oakley, J.A. Cidlowski, The biology 
of the glucocorticoid receptor: new signaling mechanisms in health and disease, 
The Journal of allergy and clinical immunology, 132 (2013) 1033-1044.) The 
Journal of Allergy and Clinical Immunology : In Practice by Elsevier. Reproduced 
with permission of Elsevier in the format Thesis/Dissertation via Copyright 
Clearance Center. 
1.3 Effects of chronic stress on disease 
Chronic psychological stress manifests in different ways in different people. 
American Psychological Association defines stress as “uncomfortable emotional 
experience accompanied by a predictable biochemical, physiological or 30  
  
behavioral changes” [26]. While acute stress is adaptive and can be beneficial 
and important from an evolutionary perspective to prepare for an imminent threat, 
chronic stress has no apparent benefits. Excessive chronic stress, which is 
constant and persists over an extended period of time either due to repeated 
stress or sudden events. Chronic stress can be physically and emotionally 
debilitating, and increase risks of disease. Longitudinal and retrospective studies 
studying the influence of psychological factors on human health and disease 
study several cohorts of people. Glaser et al, showed that individual’s response 
for pathogens was significantly different between long term caregivers compared 
to non-caregivers due to altered immune response [27]. The same authors in 
another study showed that longstanding marital stress was associated with 
decreased immune function [28].  On the other hand, positive emotions and high 
social support was associated with increased NK function [29].  In a study 
involving 557 individuals, religious attendance was also associated with 
decreased IL6 levels and consequently played a role in better survival [30]. In 
SNS, hypersensitivity occurs during chronically stressful conditions. In preclinical 
models, animals exposed to chronic and repetitive stressors are able to produce 
and store higher amounts of catecholamines. These animals however do not 
show catecholamine surge to the same extent as control animals when exposed 
to the same stressor. However, presence of a new or novel stressor elicits an 
exaggerated response indicative of hyper-responsiveness [31]. Some of the 
common physiological responses to a stressor are summarized in Table 2 [32]. 
Elevated NE levels in tissue or plasma can directly affect cell types including 
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cancer cells and the following sections summarize some of the most important 
biological effects of catecholamines. 
Table 2: Physiological response to stressor [32] 
Oxygen and nutrients directed to the 
CNS and stressed body site(s) 
Detoxification from toxic products 
Altered cardiovascular tone, increased 
blood pressure and heart rate 
Inhibition of growth and reproduction 
Increased respiratory rate Inhibition of digestion-stimulation of 
colonic motility 
Increased gluconeogenesis and 
lipolysis 
Containment of the 
inflammatory/immune response 
 
1.3.1 Clinical Depression and CES-D score  
Depression is one of clinical manifestations of chronic psychological stress. By 
definition, depression or major depressive disorder (MDD) refers to a mental 
condition characterized by lack of motivation and low mood that is persistent 
across all situations for at least 2 weeks [33]. Among all mental disorders, 
National Institute of Mental Health estimates MDD as the most common and 
estimate about 6.7% of adult population had at least one major depressive 
episode in 2015. National Comorbidity Survey was the first large scale 
epidemiological study that looked at prevalence of MDD in Americans. The study 
concluded that there was a 17% lifetime prevalence, and 6.7% of the population 
showed symptoms of MDD in the past 28 days [34]. The same study also 32  
  
showed prevalence was at 21.3% in women and 12% in men. MDD also 
accounts for the highest amount of years lost due to disability (YLD) among 
mental disorders. YLDs are commonly used to define how ailments and diseases 
affect workforce and its impact on economy. It is calculated by multiplying the 
prevalence of a disorder (physical or mental) by the short- or long-term loss of 
health associated with that disability (the disability weight) (figure 7).  
 
Figure 7: Effect of MDD on YTD. National Institute of Mental Health, Retrieved 
January 2017. https://www.nimh.nih.gov/health/statistics/disability/us-ylds-
contributed-by-mental-and-behavioral-disorders.shtml 
While certain genetic factors and biochemical factors might predispose a patient 
to MDD, psychological stressors are the major cause. In the clinic, MDD is 33  
  
assessed by Center for Epidemiological Studies-Depression (CESD) screening 
diagnosis. It was first published by Radloff in 1977 as a 20-point questionnaire 
used to quantify depressive symptoms [35]. This is a self-report questionnaire 
that is used broadly in epidemiological studies to assess clinical depression it has 
shown good reproducibility and reliability across several populations [35]. This 
reliability has been attributed to the nature of the questionnaire that focuses 
primarily on psychological and cognitive effects of depression and not physical 
parameters such as pain, loss of appetite etc. [35, 36]. A cutoff of 16 is 
considered to a good indicator of risk of clinical depression with good specificity 
and sensitivity. A correlation between cancer and high CESD have been shown 
in other cancers such as ovarian, testicular, lung cancers [37-39].In a large scale 
study comparing psychological evaluations between healthy and breast cancer 
patients, there was a significant increase in CESD scores among cancer 
patients. Not surprisingly, there was an increase in CESD score among patients 
prior to initiating treatment and midway through their treatment (table 3) [40].  
Mean CES-D scores of the patient group and healthy comparison group 
 Patient group Healthy comparison group F 
Time 1 10.9 (sd = 8.9) 8.1 (sd = 7.0) 4.71 
Time 2 12.8 (sd = 10.2) 7.8 (sd = 7.5) 11.72 
Table 3: Differences in CESD Score among healthy and breast cancer patients 
[40] (D. Hann, K. Winter, P. Jacobsen, Measurement of depressive symptoms in 
cancer patients: Evaluation of the center for epidemiological studies depression 
scale (Ces-d), Journal of Psychosomatic Research, 46 (1999) 437-443.) Journal 
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of psychosomatic research by Leigh, Denis Reproduced with permission of 
ELSEVIER INC. in the format Thesis/Dissertation via Copyright Clearance 
Center. 
In ovarian cancer, Huang et al studied ADRB status and depression symptoms 
on survival [41]. For this study, the authors studied 237 patients from the Nurse 
Health study. The anxiety and depressive symptoms were assessed using 
Crown-Crisp Experiential Index (CCEI) and ADRB2 status assessed by 
immunohistochemistry. Tumors from 19% of patients stained positive for ADRB2 
and these were also had significantly high levels of anxiety, depression 
symptoms compared with those patients bearing ADRB negative tumors. 
Dysregulation of the autonomic nervous system (ANS) is also associated with 
depressed patients with coronary heart disease. 
 
1.4 Effects of Stress on Disease 
Chronic stress has adverse effects on a number of diseases and this is 
summarized in the review below (figure 8). The following sections elaborate 
further some of the most important effects of adrenergic signaling and NE. 
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Figure 8: Effects of chronic stress on disease [42] (A.S. Nagaraja, N.C. Sadaoui, 
P.L. Dorniak, S.K. Lutgendorf, A.K. Sood, SnapShot: Stress and Disease, Cell 
Metab, 23 (2016) 388-388 e381.) Cell metabolism by ELSEVIER. Reproduced 
with permission of ELSEVIER in the format Thesis/Dissertation via Copyright 
Clearance Center. 
Some of the earliest studies on effects of chronic stress were done to evaluate its 
adverse effects on cardiovascular disease. Chronic stress effects on 36  
  
cardiovascular tissue can occur in different ways (figure 9). Plasma levels of NE 
(which is used as a biochemical indicator of adrenergic stimulation) is associated 
with mortality and cardiovascular outcomes [43]. High levels are associated with 
left ventricular dysfunction, high sympathetic activity in congestive heart failure 
[44-46]. Stress-induced endothelial dysfunction can be attributed to reduced 
vasodilation and accelerated atherosclerotic processes [47]. NE can also activate 
the renin-angiotensin-aldosterone system (RAAS) and this pathway is activated 
in patients with depressive symptoms [48-50]. Activation of aldosterone and 
mineralocorticoid receptors can result in increased pro-inflammatory cytokine 
production such as MCP1, MIF1a, and IL8 among others. NE and SNS activation 
can increase atherosclerotic plaques, several mechanisms such as increased 
cholesterol, increased macrophages, increased leukocytes, decreased vascular 
smooth muscle cells and increased likelihood of plaque rupture [51-53]. Cardiac 
tissue has an abundance of ADRB1 receptors, and resting heart rate is higher in 
depressed patients irrespective of their hypertensive status [54].  
 
Figure 9: Chronic stress and cardiovascular disease [55] A. Steptoe, M. Kivimaki, 
Stress and cardiovascular disease, Nat Rev Cardiol, 9 (2012) 360-370.) (Nature 
Reviews Cardiology by World Heart Federation Reproduced with permission of 
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Nature Pub. Group in the format Republish in a thesis/dissertation via Copyright 
Clearance Center. 
Takatsubo cardiomyopathy commonly referred to as the broken-heart syndrome 
is a temporary and reversible heart condition triggered by sudden severe or 
emotional stress (such as death of a loved one, natural calamities, motor vehicle 
accident etc) [56, 57]. This is foun  most commonly in postmenopausal women, 
and specific mechanisms are unknown. The sudden surge in catecholamine 
signaling triggers left ventricular dysfunction that can then no longer contract 
completely, resulting in the enlargement of the left ventricle to resemble a 
Japanese pot. 
1.4.1 Effects of chronic stress on immune system 
Chronic stress-induced immune dysregulation can have significant deleterious 
effects on health including blunted response to vaccination, slow and 
compromised wound healing, reactivation of latent viruses such as Herpes 
Simplex or Epstein–Barr virus (EBV), and increased risk other infectious 
diseases [58-60] (figure 10). Several human studies have shown that 
physiological stress impairs wound healing. Wound healing is a multiple step 
processes initiated by an inflammatory response, which is sequentially followed 
by proliferation (rebuilding tissue) and maturation (tissue remodeling phases). 
The first phase of wound healing requires an inflammatory response to recruit 
immune cells such as phagocytes and fibroblasts by producing chemokines and 
cytokines and this is important because when this stage is impaired, healing is 
disrupted [61, 62]. Proinflammatory cytokines such as IL6, TNF-a, IL1 are 38  
  
decreased in the wound site during psychological stress and this can delay 
healing. Psychological stress, anxiety, depression have all been attributed to 
decreased adaptive cell immunity involving both B-cells and T-cells thereby 
increasing clinical risk of diseases [60, 63]. Psychological stress mediated 
reduced cellular immunity can lead to increased recurrence of viral infections 
including the herpes viruses, influenza, Hepatitis B and Epstein–Barr virus (EBV) 
by reactivating latent viruses and altering immune responses to the virus  [64-67]. 
Mechanistically, this is due to the shift in the cytokine profile from a Th1 toward a 
Th2 profile that decreases cytokines important to mount a response against 
viruses [27]. Chronic stress is also associated with reduced NK cell activity in 
both human and animal models [68, 69].  
Chronic psychological stress has been shown to be an aggravating factor in 
inflammatory bowel disease (IBD). Catecholamines can change gut permeability 
and bacteria adherence to mucosal surface [70]. Intestine is highly innervated 
with sympathetic neurons and increased NE activated mast cells in the gut 
mucosa driving inflammation and production of pro-inflammatory cytokines [71].  
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Figure 10: Stress effects on Immune function [58] (J.P. Godbout, R. Glaser, 
Stress-Induced Immune Dysregulation: Implications for Wound Healing, 
Infectious Disease and Cancer, J Neuroimmune Pharm, 1 (2006) 421-427.) 
Journal of neuroimmune pharmacology by Society on NeuroImmune 
Pharmacology Reproduced with permission of SPRINGER NEW YORK LLC in 
the format Thesis/Dissertation via Copyright Clearance Center. 
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1.4.2 Effects of chronic stress on viral biology 
Norepinephrine and cortisol have several effects on viruses including accelerated 
replication, reactivation of latent viruses and reduced response to therapeutics. In 
a prospective study, a link was found between susceptibility to the common cold 
and levels of psychological stress [72]. Cortisol is associated with enhanced 
ability of HIV viruses to infect lymphocytes as well as immune suppression. 
Norepinephrine is shown to activate HIV replication in vitro and reduced 
response to antiviral therapy [73]. Increased HIV replication upon norepinephrine 
treatment was due to activation of protein kinase A (PKA) downstream of 
adrenergic receptors. This resulted in altered cytokine production by HIV-infected 
PBMC, particularly decreased production of IL10 and IFN-gamma [74]. Herpes 
simplex virus (HSV) can remain latent for many years in sensory and peripheral 
ganglia and stress hormones such as norepinephrine can decrease latency of 
disease. Mechanistically, this is because norepinephrine can decrease 
production of interferon-gamma which activate macrophages that fight HSV 
infection [75]. 
Unpublished data from our lab shows that NE can drive HPV-driven cervical 
cancers by increasing tumor growth and metastasis. Treating tumor-bearing 
animals with propranolol abrogated these effects. 
1.4.3 Effects on nervous system 
In patients with MDD studies looking at structural differences and functional MRI 
(fMRI) in the brain suggest several changes in the activity of specific areas in the 
brain. For example, there is hyperactivity in the ventromedial prefrontal cortex 
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and lateral prefrontal cortex that modulates pain/aggression and assesses risk 
respectively [76, 77] (figure 11). On the other hand, dorsolateral prefrontal cortex, 
that is required for sustained memory processed, show decreased activity [78]. 
The amygdala is located deep in the brain's medial temporal lobe and is the 
central component in the neural circuitry that processed emotions and pain. 
Amygdala is heavily innervated by adrenergic system and NE levels increase 
during stress [79]. Under emotional distress, amygdala is one of the main targets 
of NE during pain modulation [79]. This has been shown to predispose 
individuals to drug-seeking as well increased likelihood of drug relapse [80]. The 
hippocampus is involved with memory and learning, and chronic stress and 
stress hormones have been shown to impair both [81]. Clinical data shows that 
patients exposed to severe stressful events (such as those diagnosed with 
PTSD) show to a smaller hippocampal volume that can correlate to impaired 
memory [82].  Long term potentiation refers to a neuronal process caused by 
repeated and frequent activation of afferent fibers synapses that can strengthen 
memory formation. Preclinical studies using rats have shown that chronic stress 
can alter LTP in 2 regions of the hippocampus, CA3 and dentate gyrus [83]. In 
preclinical models, stress impairs memory by altering ensuing synaptic plasticity 
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and firing properties of hippocampal neurons [81]. In preclinical models, chronic 
stress leads to depression-like behavior, including heightened fear learning in 
presence of prey-scent, increased helplessness, fatigue and decreased 
motivation for food and other rewards [84]. 
 
Figure 11: Regions exhibited significant between-group differences in regional 
nodal parameters between control and patients with MDD [77] Figure as 
originally published M. Ye, T.L. Yang, P. Qing, X. Lei, J. Qiu, G.Y. Liu, Changes 
of Functional Brain Networks in Major Depressive Disorder: A Graph Theoretical 
Analysis of Resting-State fMRI, PloS one, 10 (2015). 
1.5 Chronic stress and cancer 
1.5.1 Clinical studies 
Psychological stress and clinical depression can affect outcomes such as 
survival and relapse in several cancers such as lung, ovarian, breast, colon and 
renal carcinomas [85-88]. Studies have also shown that clinical depression is 
common among patients with melanoma, pancreatic, prostate, ovarian, breast, or 
lung cancers [89-93]. Ovarian and breast cancers are the most widely studied 
cancer for effects of depression, social support or other biobehavioral factors. In 43  
  
a study by Lutgendorf et al, of 68 ovarian cancer patients, low social support was 
associated with elevated intratumoural NE level whereas there were no 
differences in plasma levels [85, 86]. In another epidemiological study, Costanzo 
et al. showed that in a cohort of 61 ovarian cancer patients, patients with low 
social support also had higher levels of interleukin 6 (IL-6) in blood and ascites 
[94]. A history of major depression is also associated with elevated plasma IL6 
levels in breast cancer. Renal cell carcinoma patients with high CESD score 
show a prominent pro-inflammatory signature in PBMC including high expression 
of Cox2, IL6 and other markers [86]. 
Conversely, incidental usage of a beta-blocker is shown to have survival benefits 
in several studies [95, 96] (figure 13). In one of the most comprehensive studies, 
3561 patients with high-risk prostate cancer, of whom 1115 patients had used a 
beta-blocker before and after diagnosis, use of a beta-blocker affected several 
aspects of disease. It was significantly associated with a delayed onset of 
disease, reduced risk of mortality from prostate cancer, a lower Gleason score 
and a lower rate of distant metastasis [97]. Aspirin is a widely used NSAID that 
was shown in this study to have an additive survival benefit when combined with 
a beta-blocker. On a molecular levels,  expression of ADRB2 in oral squamous 
carcinoma cells was associated with greater tumor size, higher rate of lymph 
node metastasis and advanced clinical stage in patients [96]. A retrospective 
study done on patients with epithelial ovarian cancer showed that use of a beta-
blocker increased both progression-free and overall survival when compared to 
patients who had never used a beta-blocker. Several clinical studies support the 
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beneficial role of beta-blockers in breast cancer as well. In a cohort of 466 breast 
cancer patients, 43 patients who were on a non-specific or ADRB1-targeted beta-
blocker (atenolol) for hypertension had significantly prolonged survival and lower 
rates of metastasis as well as recurrence [98, 99]. In a contradictory study, 
Barron et al. grouped breast cancer patients into those not on a beta-blocker, 
those on atenolol (beta-1 selective) and those on propranolol (non-selective beta 
blocker) [98]. Significant survival benefit was seen only among patients who were 
on propranolol, and not on those on atenolol. Past therapy with propranolol was 
also associated with lower tumor grade and lower incidence of metastasis than in 
patients not on a beta-blocker. Use of a beta-blocker was associated with 
reduced risk of death in patients with malignant melanoma. In a recent 
retrospective study in non–small cell lung cancer, use of a beta-blocker (ADRB1 
specific or non-selective) during radiation therapy was associated with 
significantly better rates of overall survival, distant metastasis-free survival and 
progression-free survival. In infantile haemangioma, propranolol is one of the 
most promising options for therapy, as it decreases expression of VEGF, which is 
vital in progression of this disease [100]. Propranolol is not approved by FDA for 
pediatric cancers, but it has been used to treat cardiac ailments in children and is 
documented to be well tolerated, with side effects that are seldom life 
threatening. There are currently clinical trials underway to assess propranolol 
(NCT01908972, NCT01211080), nadolol (NCT01010308), timolol 
(NCT02731287) and other beta-blockers for treatment of hemangioma. Beta-
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blocker usage is associated with decreased cancer-related mortality, using data 
from the FDA Adverse Event Reporting System (figure 12) [101]. 
 
Figure 12: Effect of beta-blocker on cancer-related mortality [101]. (G.N. Armaiz-
Pena, J.K. Allen, A. Cruz, R.L. Stone, A.M. Nick, Y.G. Lin, L.Y. Han, L.S. 
Mangala, G.J. Villares, P. Vivas-Mejia, C. Rodriguez-Aguayo, A.S. Nagaraja, 
K.M. Gharpure, Z. Wu, R.D. English, K.V. Soman, M.M. Shahzad, M. Zigler, M.T. 
Deavers, A. Zien, T.G. Soldatos, D.B. Jackson, J.E. Wiktorowicz, M. Torres-
Lugo, T. Young, K. De Geest, G.E. Gallick, M. Bar-Eli, G. Lopez-Berestein, S.W. 
Cole, G.E. Lopez, S.K. Lutgendorf, A.K. Sood, Src activation by beta-
adrenoreceptors is a key switch for tumour metastasis, Nature communications, 
4 (2013) 1403.) Nature communications by Nature Publishing Group. 
Reproduced with permission of Nature Publishing Group in the format Republish 
in a thesis/dissertation via Copyright Clearance Center. 46  
  
1.5.2 Preclinical models for chronic stress 
Preclinical models of chronic stress are difficult to recapitulate when we try to 
mimic all the psychological workings of chronic stress in humans. Biobehavioral 
symptoms and signs of clinical depression such as suicidal thoughts, low self-
esteem and mood swings are impossible to obtain in preclinical models.  Hence, 
scientists use predicted molecular and physiological responses to depression to 
evaluate animal models (table 4) [102]. Restraint stress is one of the most widely 
used models to mimic clinical depression for several reasons. This model 
enables reliable assessment of stress-related biobehavioral and biochemical 
changes in laboratory animals. The test is also easy to perform and has high 
reproducibility. Restraint stress enables us to study both acute and chronic 
stress, and produce a mental stress to animals that have low adaptability.  In 
addition, this test is also painless for the animals, and would not trigger other 
pathways (such as hypothermia, pain) that might contribute to tumor growth. 
Some of the other widely used preclinical models are summarized in the table 
below. 
Table 4: Animal models of chronic stress 
Model  Advantages 
Tail Suspension Mice suspended from tail, time to 
reach up measured 
Easy to perform 
Wet bedding Bedding of cage kept damp Easy to perform 
Learned 
helplessness 
Exposure to uncontrollable  and 
unpredictable stressors Foot shock  
Easy to perform 
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Maternal 
deprivation 
Early stage stress model Induces anxiety 
symptoms 
Forced swim test Model for behavioral despair where 
time to escape is measured 
Easy to perform 
 
1.5.3 Effects on tumor initiation 
Very little preclinical evidence shows a role for stress in driving tumor initiation. 
Saul et al, used SKH1 which is a melanoma model susceptible to UV-induced 
tumors to study effects of chronic stress on tumor initiation. Restraint stressed 
animals had a shorter time to occurrence of the first tumor, which can be 
interpreted as shortened latency to disease as true initiation. The stressed 
animals also had high levels of proinflammatory cytokines and reduced T-helper 
cells compared to controls [103]. In another model of melanoma, chemically 
induced tumors using 7,12-dimethylbenz(a)anthracene (DMBA) alone (topical), 
and DMBA-12-O-tetradecanoylphorbol-13-acetate (TPA) after chronic 
unpredictable stress increased tumor incidence and tumor burden [104]. 
Innervation of peritumoral or intratumoral regions can produce catecholamines 
and is increasingly shown to play roles in tumor progression in prostate, 
pancreatic and ovarian cancers [105-108]. However, definite causation of tumors 
owing to increased adrenergic stimulation is not well studied. 
1.5.4 Direct effects on cancer cells 
Some of the first studies looking at the molecular effects of norepinephrine on 
cancer cells were done in ovarian cancer. Using restraint stress, Thaker showed 48  
  
that chronic restraint stress can lead to increased tumor growth and metastasis 
[109]. Several cancer cells are positive for ADRB receptors. Activation of these 
receptors activates transcription factors such as CREB, PKA and Nf-kB. Thaker 
and Shahzad showed in independent studies that chronic stress increases levels 
of VEGF and IL8 in an ADRB2 dependent manner thereby promoting 
angiogenesis [109]. Sood et al also showed that NE and ADRB2 mediated 
signaling can promote cell survival during anoikis that can further help 
disseminated cells to metastasize effectively to distant organs [110]. Armaiz-
Pena et al, showed that NE can potently induce metalloproteinases (such as 
MMP2 and MMP9), Src, and FAK activation in cancer cells and contribute to 
metastasis [101]. Hassan et al showed that NE could activate anti-apoptotic 
signaling in a PKA-dependent manner and promote cell survival in a model of 
prostate cancer [106]. In vitro studies in ovarian, colon, melanoma and 
pancreatic cancer cell lines have shown NE can potently increase invasion and 
migration of cells [111-114]. NE can also promote inflammation by increasing 
PGE2 levels in an ADRB2-Nf-kB-PTGS2 axis in ovarian cancer [115]. NE can 
also blunt effects of chemotherapy and anti-angiogenic therapy. Kang et al, 
showed that NE can reduce effects of platinum and paclitaxel therapy in ovarian 
cancer via NE-ADRB2-Jnk-DUSP1 pathway [116]. Preclinical models of lung and 
colorectal cancers show that chronic stress can decrease the therapeutic benefit 
of sunitinib by increasing VEGF, IL8 and these effects can be blocked by 
propranolol. [117, 118].  In preclinical in vivo and in vitro studies, blocking NE 
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using propranolol or specific beta-blockers can abrogate tumor growth, 
metastasis or angiogenesis [107, 108]. 
1.5.5 Effects on stromal cells  
There are an increasing number of studies that have shown that stromal factors 
contribute significantly to all aspects of tumor progression including growth, 
metastasis, immune suppression, angiogenesis, resisting cell death [119]. There 
are several infiltrating immune cells such natural killer cells, tumor associated 
macrophages, and T and B-lymphocytes. Tumor associated macrophages 
produce VEGFA, an important factor in promoting angiogenesis, and can also 
produce several proinflammatory cytokines. NK cells are cytotoxic lymphocytes 
of the innate immune system that produce cytotoxic granules containing perforin 
and various granzymes upon activation and cause perforations and apoptotic 
death of tumor cells. Impaired NK cells or NK cell deficiency is associated with 
increased incidence of cancer in preclinical models and human studies [120].  T 
cells in tumors have been studied intensively over the past years and with 
immunotherapy, is emerging as one of the main targets to treat various cancers. 
Antibodies against checkpoint inhibitors such as CTLA4 or PD1 have shown 
complete or partial response in renal cell carcinoma, head and neck cancer, 
melanoma, lung cancer among others [121].  In several cancers, low cytotoxic T-
cell infiltration (CTL) within tumors is associated with low survival. The 
proinflammatory microenvironment is considered to one of the most important 
impediments to T-cell infiltration [121].  Tumor associated endothelial cells have 
weak intercellular connections resulting in a leaky vasculature that can contribute 
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to metastasis. In addition they can a) produce several growth factors, b) engage 
leukocytes and platelets and play a role in trafficking of immune cells and c) 
produce factors such as PGE2, VEGF that impede T-cell infiltration into tumors 
[122]. Some of the other cell types and their most important roles are 
summarized in figure 13. 
 
Figure 13: Stromal contributions to tumor progression.[119] (D. Hanahan, L.M. 
Coussens, Accessories to the crime: functions of cells recruited to the tumor 
microenvironment, Cancer Cell, 21 (2012) 309-322.) Cancer cell by CELL 
PRESS. Reproduced with permission of CELL PRESS in the format 
Thesis/Dissertation via Copyright Clearance Center. 
51  
  
 Effects of NE on stromal cells have not been as well studied as tumor cells 
(figure 14). Armaiz-Pena et al showed that NE induced MCP1 production by 
cancer cells can promote tumor-associated macrophages in ovarian cancer 
[123].  Sloan et al, showed the NE-induced elevations in tumor-associated 
macrophages increased breast cancer metastasis [124]. Ben-Eliyahu et al, 
showed that in models of breast cancer and leukemia, NK cell activity was 
suppressed during chronic stress and could attribute to increased tumor growth 
[125, 126]. A study in brain cancer shows tumor endothelial cells are positive for 
adrenergic receptors and can promote tubulogenesis and MMP9 secretion and 
propranolol can block this effect [127, 128]. Infantile hemangioma is an 
endothelial-derived tumor in which the first line of therapy is propranolol [129].  
 
Figure 14: Effects of catecholamines on cancer and stromal components [88] 
(S.W. Cole, A.S. Nagaraja, S.K. Lutgendorf, P.A. Green, A.K. Sood, Sympathetic 
nervous system regulation of the tumour microenvironment, Nature reviews. 
Cancer, 15 (2015) 563-572.) Nature Reviews Cancer by NATURE PUBLISHING 
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GROUP. Reproduced with permission of NATURE PUBLISHING GROUP in the 
format Republish in a thesis/dissertation via Copyright Clearance Center. 
1.6 Cancer associated fibroblasts 
A typical tumor contains endothelial cells, pericytes, immune cells such as 
macrophages, T- and B-cells, cancer-associated fibroblasts, adipocytes and 
other non-cellular components such as extracellular matrix and basement 
membrane. Among them CAFs are usually the most abundant stromal cell in 
tumors and play important roles in tumor progression. Once thought to be mere 
bystanders, CAFs are currently studied extensively due to emerging studies that 
show roles in chemoresistance, resistance to immunotherapy, metastasis and 
invasion [130-132]. 
1.6.1 Definitions 
CAFs can also be referred to as tumor-associated fibroblasts, activated 
myofibroblasts or simply activated fibroblasts (figure 15) [133, 134]. Resident 
fibroblasts in most normal tissue are resting or quiescent, however they become 
‘activated’ during tissue injury and during presence of tumor cells. The cues that 
trigger activation during wound healing is known but cues during tumor growth 
are not studied well. Activated fibroblasts in both cases however show similar 
characteristics in that they produce a number of cytokines, increase collagen 
production, and show presence of certain markers of activated CAFs [134]. 
Functionally, these can have several growth-promoting effects on a tumor. 
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Figure 15: Activation of fibroblasts [133] (R. Kalluri, The biology and function of 
fibroblasts in cancer, Nat Rev Cancer, 16 (2016) 582-598.) Nature Reviews 
Cancer by NATURE PUBLISHING GROUP. Reproduced with permission of 
NATURE PUBLISHING GROUP in the format Republish in a thesis/dissertation 
via Copyright Clearance Center. 
1.6.2 Origin and markers 
There is wide heterogeneity in CAFs and hence, there are several markers that 
are taken together to identify them. Alpha-Smooth muscle actin (a-SMA) is the 
most widely used CAF marker to identify tumoral fibroblasts and other markers 
include fibroblast-activated protein (FAP), fibroblast-specific protein-1 
(FSP1/S100A4), neuron-glial antigen-2 (NG2) and PDGF β-receptor. Several of 
these markers are common with other cells within tumors such as smooth 
muscles (a-SMA), pericytes (NG2) and tumor cells (PDGFR-b). Morphologically 54  
  
similar CAFs may not stain positive for the same markers, and hence scientists 
believe that there are a subset of CAFs in tumors [131, 133]. 
CAFs can also be derived from several sources, but primarily from 2 sources: 
residual fibroblasts or recruitment of mesenchymal stem cells into tumors (figure 
16). Several studies of colon, breast and lung cancers suggest that local 
activation of fibroblasts contributes to CAFs in tumors [135]. Marini et al, used a 
lethally irradiated RFP+ mice which were reconstituted with GFP+ bone marrow 
to study local and bone-marrow derived stromal components in ovarian cancer 
[136]. Using several markers for CAFs such as a-SMA, NG2, FSP and FAP, they 
showed that a-SMA+ and NG2+ CAFs were derived from local tissue. FSP+ and 
FAP+ cells co-stained with GFP indicating mesenchymal stem cell origin [136]. 
There is some evidence to show that epithelial cells exposed to reactive oxygen 
species or MMPs during fibrosis can transdifferentiate into a CAF-like cell, which 
can deposit ECM proteins and stains positive for a-SMA [137]. Preclinical studies 
using GEM models with tagged lineages show that endothelial cells can also 
show CAF-like phenotype in a process called EndMT (endothelial to 
mesenchymal transformation) in melanoma [138]. 
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Figure 16: Origin of fibroblasts [132] (A. Ostman, M. Augsten, Cancer-associated 
fibroblasts and tumor growth - bystanders turning into key players, Curr Opin 
Genet Dev, 19 (2009) 67-73.) Current opinion in genetics & development by 
ELSEVIER LTD.. Reproduced with permission of ELSEVIER LTD. in the format 
Thesis/Dissertation via Copyright Clearance Center. 
1.6.3 Functional roles in tumor microenvironment 
Clinical studies have shown that higher levels of CAFs in colon, ovarian, lung, 
and breast cancers are all associated with decreased survival [139, 140]. The 
role of CAFs in driving tumor initiation and progression is multi-faceted (figure 
17). When CAFs are co-incubated with premalignant cells, they can induce 
tumors and promote malignancy [141]. CAFs can directly affect and increase 
tumor growth. Activated fibroblasts produce a number of potent growth factor 
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such as HGF, IL6, EGF and CTGF [130, 131, 139, 140, 142, 143]. These can 
activate downstream signaling in tumor cells that promote both growth and 
metastasis. CAF-derived prostaglandin E2 can also reduce NK cell activity in 
tumors [144]. VEGF, TGFb, PDGFa derived from CAFs can stimulate endothelial 
cell growth promoting angiogenesis [145-147]. CAFs also produce several ECM 
proteins such as collagens that provide both signaling and scaffolding for tumor 
metastasis. MMPs and TIMPs help breakdown ECM proteins as needed for 
tumor growth. One of the biggest functions of CAFs is decreasing cell-mediated 
immunity. CAFs produce several extracellular factors such as GM-CSF, IL6, 
TGFb, CCL2, CCL5 that impede immune cell recruitment particularly T-cells. 
 
Figure 17: Functions of CAFs [148] (R. Kalluri, The biology and function of 
exosomes in cancer, J Clin Invest, 126 (2016) 1208-1215.) Nature Reviews 
Cancer by NATURE PUBLISHING GROUP. Reproduced with permission of 
NATURE PUBLISHING GROUP in the format Republish in a thesis/dissertation 
via Copyright Clearance Center. 
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1.7 Activin Signaling 
Activins and inhibins are members of the TGF-b family of proteins. In normal 
tissue, it is primarily expressed reproductive tissue such as gonads, uterus and 
pituitary owing to its role in development of ovary, testis and follicle [149]. Inhibin, 
beta A is also shown to play a role in driving glucose stimulated insulin secretion 
in pancreatic beta-cells (figure 18) [149]. Inhibin, Beta A can drive SMAD 
signaling via heteromeric complexes and activation of AVR2a and ACVR2b 
receptors. Phosphorylation of SMADs 2/3 and SMAD4 complex leads to their 
translocation to the nucleus. Here the proteins can bind to specific sequences in 
the genome called SMAD binding element (SBE) and can drive transcription of 
several genes [150].  
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Figure 18: Inhibin, Beta A Signaling [150]. Figure as originally published in 
Metpally RPR, Nasser S, Malenica I, Courtright A, Carlson E, Ghaffari L, Villa S, 
Tembe W and Van Keuren-Jensen K (2013). Front. Genet. 4:20. 
1.7.1 Inhibin, Beta A in cancer 
Inhibin, Beta A (INHBA) is overexpressed in several cancers including prostate, 
ovarian, pancreatic, breast, colon and other cancers. Inhibin, Beta A is 
overexpressed in late-stage colon cancer patients compared to normal and early 
stage disease [151]. In breast cancer patients, Inhibin, Beta A was 
overexpressed invasive ductal carcinoma compared to normal breast tissue 
[152]. Immunohistochemical staining also showed elevated p-SMAD2 and p-
SMAD3 in tumor samples compared to normal tissue. Recombinant Inhibin, Beta 
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A increased anchorage-independent growth in breast cancer cell lines MCF7 and 
MDA-MB-231 were used to study biological effects of Inhibin, Beta A [152]. In 
vivo studies using Inhibin, Beta A-overexpressing cell line showed increased 
tumor growth, metastasis and EMT. In prostate cancer, Inhibin, Beta A up-
regulates expression of AKR1C3 (Aldo-Keto Reductase Family 1 Member C3) 
which is important for driving intratumoral levels of androgen. High levels of 
Activin was also associated with worse survival in prostate cancer [153]. In 
ovarian cancer, Inhibin, Beta A levels are higher in cancer compared to normal 
and plays a role in promoting invasion and migration of cancer cells [154].  
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2 Rationale and Significance 
Several epideminiological and preclinical studies have shown that psychological 
factors can have adverse effects on human health. These include increased 
incidence of cardiovascular disease, inflammatory bowel disease, type 2 
diabetes. Altered mental states such as depression or chronic stress, potently 
activates the sympathetic nervous system to produce catecholamines either by 
adrenal glands or local production by peripheral nerves.  Recent evidence has 
shown that cancer cells have receptors for catecholamines, and can promote 
tumor growth, angiogenesis, inflammation, and macrophage infiltration. For this 
project, we sought to find a link between high levels of tumoral catecholamines 
and stromal components within ovarian tumors. I hypothesized that sustained 
adrenergic signaling during chronic stress can accelerates induction of a CAF-
phenotype in ovarian tumors. My work demonstrates a) there is a prominent 
stromal signature in patients with high depressive symptoms compared to those 
with low depressive symptoms b) this is due to increased production of INHBA 
(Inhibin, beta A) by cancer cells after NE stimulation in an ADRB2-CREB axis 
and c) this results in activation of fibroblasts and these can increase collagen 
levels in the tumor stroma. Together these data represent the first demonstration 
that adrenergic signaling mediated Inhibin, beta A can drive CAF phenotype in 
ovarian tumors. This work provides evidence that blocking Inhibin, beta A in 
combination with beta-blockers may be a viable therapeutic target in chronically 
stressed patients in order to block the deleterious effects of chronic stress on 
patient outcome.  
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3 Methods 
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3.1 Cell lines 
Skov3-ip1, A2780-ip2and HeyA8 ovarian cancer cell lines have been described 
previously [101]. They were maintained in RPMI-1640 medium supplemented 
with 15% fetal bovine serum and 0.1% gentamycin sulfate at 37°C. The ID8-ip1 
murine ovarian cancer cell line was maintained in DMEM-high glucose medium 
supplemented with 10% fetal bovine serum, 0.1% gentamycin, and 0.1% insulin-
transferrin sulfate [155]. NOF151 normal ovarian fibroblasts, whose derivation 
has been described before [139, 156], were a kind gift from Dr. Jinsong Liu. 
These cells were maintained in a 1:1 mixture of Medium 199 and MCDB 105 
medium supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin, 
and 5 µg epidermal growth factor. All cells were grown at 37°C in a humidified 
chamber with 5% CO2. 
For all in vitro experiments, cancer cells at 70% confluence were serum-starved 
overnight before treatment. NE (10 μM; Sigma-Aldrich, St Louis, MO, USA) was 
dissolved in sterile water just before it was added to the cells. Isoproterenol and 
terbutaline (Sigma-Aldrich) were used at published concentrations [115, 116]. 
Propranolol and butoxamine were purchased from Tocris (Bristol, UK) and used 
at published concentrations [115, 116]. Treatment with an antagonist, if pertinent, 
began 1 h before NE was added to the cell culture medium. Treatment with 
agonists was started at the same time as NE treatment. Genes were silenced by 
using a reverse-transfection protocol with RNAimax and control siRNA 
(sequence: UUAUGCCGAUCGCGUCACA Sigma-Aldrich), specific human 
INHBA siRNA (sequence: CCAACAGGACCAGGACCAA Sigma-Aldrich), human 
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ADRB2 siRNA (sequence: GCCATTACTTCACCTTTCA Sigma-Aldrich), human 
ACVR2a siRNA (sequence: GCUCCAACCUCGAAGUAGA Sigma-Aldrich) and 
human ACVR2b (CUCGACUUUGGGUUGGCCUU Sigma-Aldrich) according to 
the manufacturer's recommendations. Briefly, 40 nm siRNA was mixed with 
RNAimax transfecting agent and added to culture medium for 4 h. Fresh 
complete medium was added and cells were allowed to grow. Silencing was 
assessed at 48 h using quantitative reverse-transcriptase polymerase chain 
reaction (qRT–PCR) analysis.  
3.2 Chronic stress model 
All animal experiments were approved by the Institutional Animal Care and Use 
Committee at The University of Texas MD Anderson Cancer Center, where the 
experiments were carried out. Experiments involving human cancer cell– and 
murine cancer cell–derived mouse tumor models were performed in 8- to 12-
week-old female athymic nude and C57/B6 mice, respectively, obtained from 
Taconic Farms (Hudson, NY, USA).  Adrenalectomized mice were received from 
Taconic Farms 3 days after surgery and were given an additional 10 days to 
recover before restraint stress started. Chronic stress was induced 
experimentally by using a restraint-stress procedure that has been previously 
described [109]. In brief, mice were enclosed in a movement-restricted space for 
2 h daily for the duration of the experiment (figure 19).  
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Figure 19: Restraint system set up [109]. (P.H. Thaker, L.Y. Han, A.A. Kamat, 
J.M. Arevalo, R. Takahashi, C. Lu, N.B. Jennings, G. Armaiz-Pena, J.A. 
Bankson, M. Ravoori, W.M. Merritt, Y.G. Lin, L.S. Mangala, T.J. Kim, R.L. 
Coleman, C.N. Landen, Y. Li, E. Felix, A.M. Sanguino, R.A. Newman, M. Lloyd, 
D.M. Gershenson, V. Kundra, G. Lopez-Berestein, S.K. Lutgendorf, S.W. Cole, 
A.K. Sood, Chronic stress promotes tumor growth and angiogenesis in a mouse 
model of ovarian carcinoma, Nature medicine, 12 (2006) 939-944.) Nature 
medicine by NATURE PUBLISHING GROUP. Reproduced with permission of 
NATURE PUBLISHING GROUP in the format Republish in a thesis/dissertation 
via Copyright Clearance Center. 
Tumor cells were injected intraperitoneally into mice in all groups a week after 
the stress procedure began (Skov3-ip1: 1 million cells/animal, HeyA8: 250,000 
cells/animal, ID8-ip1: 2 million cells/animal). Mice were randomly assigned to 
groups (n=10/group), and siRNA (3.5 µg in DOPC) treatment was started 5 days 
after tumor cell injection and continued twice weekly for the duration of the 
experiment. Mice were treated by intraperitoneal injection with propranolol or a 
specific beta-blocker or adrenergic agonist daily for the duration of the 
experiment. The animals were sacrificed by cervical dislocation when they 
became moribund; the cadavers were examined for visible disease, and mouse 65  
  
weight, tumor weight, and number and distribution of nodules was noted by a 
gynecologic oncologist blinded to the treatment groups.  
3.3 siRNA delivery to tumors 
Gene silencing was done using specific sequences incorporated into DOPC 
nanoparticles as previously published [157, 158]. In short, siRNA is mixed with 
DOPC in the presence of excess tertiary butanol at a ratio of 1:10 (w/w) 
siRNA/DOPC. Tween20 is used as surfactant in the mixture, and the resulting 
product is vortexed, frozen in acetone/dry ice bath and lyophilized. Particles are 
hydrated with 0.9% saline before in vivo administration. Figure 20 shows delivery 
of siRNA at the tumor site.  
 
Figure 20: Tumors after delivery of siRNA in DOPC show siRNA in tumor, not 
clustered near the vasculature (CD31 in green) [158]. (C.N. Landen, A. Chavez-
Reyes, C. Bucana, R. Schmandt, M.T. Deavers, G. Lopez-Berestein, A.K. Sood, 
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small 
interfering RNA delivery, Cancer Res, 65 (2005) 6910-6918.) Cancer research : 
the official organ of the American Association for Cancer Research, Inc. by 
INTERNATIONAL CANCER RESEARCH FOUNDATION ; WILLIAM H. 66  
  
DONNER FOUNDATION Reproduced with permission of AMERICAN 
ASSOCIATION FOR CANCER RESEARCH in the format Thesis/Dissertation via 
Copyright Clearance Center. 
3.4 Immunofluorescence 
Frozen slide-mounted tumor sections were fixed in acetone and washed in PBS. 
Slides were incubated with the following primary antibodies overnight: α-SMA 
(1:100, Abcam, Cambridge, MA, USA), FAP (1:100, R&D Systems, Minneapolis, 
MN, USA), GFP (1:500, Abcam), and RFP (1:100, Abcam). AlexaFluor488 and 
AlexaFluor594 fluorochromes (Jackson ImmunoResearch, West Grove, PA, 
USA) conjugated to secondary antibodies were used for primary antibody 
detection. Nuclei were identified by Hoechst stain (Invitrogen, Carlsbad, CA, 
USA). 
3.5 Immunohistochemistry 
Both frozen and paraffin sections were used for immunohistochemical analyses. 
Paraffin sections were heated for 20 min at 56°C and were deparaffinized in 
xylene and dehydrated-rehydrated in decreasing grades of alcohol and PBS. 
Antigen retrieval was performed in citrate buffer (pH 6.0) in the steamer for 30 
min. Frozen sections were fixed in acetone and acetone-chloroform. After 
endogenous peroxide blocking with hydrogen peroxide in methanol and three 
washes with PBS, the slides were incubated with primary antibodies α-SMA 
(1:100, Abcam), FAP (1:100, R&D Systems), or Inhibin, Beta A (1:100, Abcam) 
overnight at 4°C. Sections were exposed to matching secondary antibodies 
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(Jackson ImmunoResearch) for 1 h at room temperature and staining was 
developed using 3,3'-diaminobenzidine. Nuclei were stained with hematoxylin. 
3.6 Migration assay 
Migration of NOF151 were measured in vitro. Inserts (8 μm; Millipore, Billerica, 
MA, USA) were coated with 1% gelatin for migration assays. A total of 50,000 
cells were placed in each upper well and allowed to move toward conditioned 
medium in the lower chamber in the presence or absence of NE. Migration was 
assessed 6 h after treatment by fixing the cells in Protocol Hema3 (Thermo 
Fisher Scientific, Waltham, MA, USA). Cells were counted in randomly chosen 
high-power fields, and cell counts are reported as average numbers of cells 
migrated. 
3.7 Collagen staining 
Collagen distribution and density were assessed by using Masson trichrome 
staining (Abcam) for both paraffin and frozen slides. Paraffin sections were 
deparaffinized and dehydrated-rehydrated in alcohols and distilled water, and 
frozen slides were dried at room temperature followed by fixation in formalin for 
30 min. Slides were then fixed in preheated Bouin Solution (Sigma-Aldrich). 
Slides were washed in tap water until the water ran clear, and Abcam’s staining 
protocol was followed. Nuclei were stained with Weigert iron hematoxylin. Sirius 
Red/Fast Green Collagen staining for collagens 1 and 3 was done by using a kit 
(Chondrex, Redmond, WA, USA). 
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3.8 qRT–PCR 
Total RNA was extracted from cells by using the Zymo Research RNA isolation 
kit with TRIzol reagent (Invitrogen) according to the manufacturer's standard 
protocol. Complementary DNA was synthesized from 1 μg of total RNA using the 
Verso cDNA Synthesis kit (Thermo Fisher Scientific) according to the supplier 
protocol, using random hexamers and oligo-dT primers in a 3:1 ratio. Quantitative 
PCR was performed using SYBR Green Master Mix on the 7500 Real-Time PCR 
System (Applied Biosystems, Carlsbad, CA, USA) and standard protocols. The 
primer sequences used are included in tables 5 and 6. 
B-actin AGCCTCGCCTTTGCCGA CTGGTGCCTGGGGCG 
ACTA2 CCAGAGCCATTGTCACACAC CAGCCAAGCACTGTCAGG 
INHBA ATCTCGAAGTGCAGCGTCTT GGAGGGCAGAAATGAATGAA  
S100A4 TGTTGCTGTCCAAGTTGCTC AACTAAAGGAGCTGCTGACC
C 
FAP TCAGTGTGAGTGCTCTCATTG
TAT 
GCTGTGCTTGCCTTA
TTGGT 
ADRB2 TCCACCTGGCTAAGGTTCTG TGTCCTTCTACGTTCCCCTG 
ACVR2a GAAAGCCCAGTTGCTTAACG GAAAGCCCAGTTGCTTAACG 
ACVR2b TGAGTACATGCTGCCCTTTG TAATGGTGGGCCTCATCTTC 
COL3A1 GATGGGGTCAAATGAAGGTG GTGTGTTTCGTGCAACCATC 
COL5A1 AGGATTTCCTGGACCAAAGG TCTTGCCTTGGAAACCAGTC 
COL5A2 CGGTGAAGAAGGCAAAAGAG TTCTCCTTGAGCACCCTTTG 
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COL11A
1 
TCCTGGTGAAAAAGGACCAC TTCTTTCCCAGGATGACCAG 
CREB 
pos1  
ACAACCCTTCACCGTTCTTG ATAGGGGTAAAGCTGGTCAG
G 
CREB 
neg  
GAGATTCTAAAGACCTGGGAA
GG 
CGACCCCAACCAACTTACAC 
Table 5: Human Sequences (*ChIP primers) 
B-actin GCTACAGCTTCACCACCACA TCTCCAGGGAGGAAGAGGAT 
ACTA2 GTTCAGTGGTGCCTCTGTCA ACTGGGACGACATGGAAAAG 
S100A4 TTTGTGGAAGGTGGACACAA CAGCACTTCCTCTCTCTTGG 
FAP CTTTGTGTTTCCTTCAGGTTTG CTTTGGAGTTACCACCCTGG 
ACVR2a GGCGACATTGTTTTGCTACC AGCCAACAACCTTGCTTCAC 
ACVR2b CTTTAAGCCCTTGCCTTTCC TCACAGCCACAAAGTCGTTC 
COL3A1 AGGATCTGTCCTTTGCGATG TCTCCAAATGGGATCTCTGG 
COL5A1 TGAACAGATGAAGCGACCAC TATTCGCCATCTGGGAAGTC 
COL5A2 TCCTCAGGGAATTGATGGAG GCCATCTGAGCTGAAAAAGG 
COL11A
1 
TGGTCATCCTGGGAAAGAAG ACCCTTTTCGCCTTTAGAGC 
Table 6: Murine Sequences 
3.9 Proteome profiler 
NOF151 cells were exposed to serum-free medium, medium conditioned by 
untreated cancer cells, or medium conditioned by NE-treated cancer cells. The 
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conditioned media were spun down at 1200 rpm to remove cell debris. Total 
protein from each culture was quantified according to Bradford protein assay, 
and 250 μg of each protein sample was assayed in parallel using a Human 
Cytokine Array kit (R&D Systems) according to the manufacturer’s protocol. 
3.10 Inhibin, Beta A ELISA 
The Inhibin, Beta A ELISA kit was obtained from MyBiosource (San Diego, CA, 
USA). Supernatants from HeyA8 cells treated with NE or a specific beta-blocker, 
and with control or INHBA siRNA, were collected and spun down to remove cell 
debris. Supernatants were immediately stored at -80°C until use. The ELISA kit 
was used per the manufacturer’s instructions. In short, a plate was incubated 
with standards or 1:10 diluted supernatants for 2 h. The plate was then incubated 
with biotin-labeled antibody for 1 h. After the plate was washed with PBS, it was 
developed with colorimetric reagent and read at 540nm. Results are expressed 
as pg protein/million cells. 
3.11 Clinical samples 
3.11.1 Renal cell carcinoma  
Single cell suspension of patient tumor samples snap frozen at time of tissue 
collection was obtained from the Department Behavioral Science at MD 
Anderson Cancer Center. The protocols for handling and analyzing the 
specimens were approved by the MD Anderson Institutional Review Board.  
Patients provided written informed consent for the collection of specimens and 
clinical data in accordance with the ethics guidelines of and with approval from 
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the MD Anderson Institutional Review Board [86].  Patients were also completed 
several psychosocial questionnaires. The Centers for Epidemiologic Studies - 
Depression was used to assess depressive symptoms, with scores of 16 or 
above classified as meeting screening criteria for depressive symptoms with 
further evaluation recommended. 9 patients with stage 2 or 3 patients with 2 
females and 2 males in low CESD score (CESD<10) and 3 males and 2 females 
with high CESD score (CESD Score>20) were chosen for analysis.  
3.11.2 Ovarian Cancer  
Gene expression array results from GSE9116 were used to assess stromal 
content in primary ovarian cancer patients with known depression scores. For 
this dataset, tumor samples and psychosocial and behavioral data was obtained 
from patients undergoing surgical resection of ovarian carcinoma. The protocols 
were approved by Institutional Review Boards at University of Iowa, University of 
Miami, and University of California Los Angeles. In short, 0.1 g of tumor was 
processed for total RNA, and genome-wide transcription analyzed using 
Affymetrix U133A high density oligonucleotide arrays.  
3.11.3 Ovarian Cancer survival data using KMPlot 
Primary ovarian cancer samples from The Cancer Genome Atlas (TCGA) was 
used to survival graphs using an online tool[159]. In short, this tool uses gene 
expression data (Affymetrix platform) from 522 patients to generate overall and 
progression-free survival using the probe 210511_s_at for INHBA. The samples 
were split by the median value and best cutoff was selected automatically. All 
stages, histology, TP53 and debulking statuses were included in the analysis. 72  
  
3.12 Bioinformatics analysis  
3.12.1 Netwalker 
NetWalker was used to analyze whole tumor gene expression data from ovarian 
cancer patients with known CES-D scores. For this scale, scores of 14 or less 
are considered low stress and scores of 15 or 16 are considered high 
stress. Unbiased networks of upregulated and downregulated genes were 
developed by using Netwalker and Ingenuity Pathway Analysis. Analyses were 
run considering the ratio (average of High stress/low stress). The network with 
the highest scoring interactions throughout was identified, along with the 
functions of the genes involved. 
3.12.2 Oncomine 
To identify genes that are significantly correlated with INHBA, we analyzed the 
TCGA datasets for ovarian, colorectal, and breast cancers using Oncomine. 
Significantly co-expressed genes from ovarian, breast, and colorectal cancers 
were identified and tabulated. 
3.12.3 RNA-Seq data 
From the Level 3 (public) data from TCGA, including values from RNA-Seq 
assays, we generated plots that included summary values for INHBA from “RNA-
SeqV2” across all tumor types, including all samples for which these data were 
available. The samples are ordered by tissue type.  
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3.12.4 Statistical analyses 
MS Excel or GraphPad Prism software was used to analyze data. Continuous 
variables were compared by using the Student t-test or analysis of variance 
(ANOVA), and the Mann-Whitney test was used to compare differences. We 
determined that, using 2-way ANOVA, a sample size of 10 animals per group 
would provide an effective size of 1.3 with 80% power at a significance of p=0.05. 
We considered p<0.05 to be significant. All statistical analysis results were 
expressed as mean ± standard error of the mean. 
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4 Results 
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4.1 Stromal signature in ovarian tumors from patients with chronic 
adrenergic activation 
My first goal was to identify potential pathways affected by adrenergic signaling. 
We accomplished this by first comparing high-grade serous cancers (HGSC) 
primary tumors from patients who had a high score on the CES-D from patients 
who had a low CES-D score and low tumoral NE levels. CES-D is a widely used 
self-report questionnaire to study depression in populations as this test has very 
high internal consistency and adequate retest reliability. These data were 
collected from a prospective cohort study (GEO GSE9116) [85] and we selected 
for genes that were significantly upregulated in the tumors of patients with high 
depressive symptoms (by at least 2-fold at the p<0.05 level). With the genes, we 
then performed an unbiased analysis of gene expression networks using 
NetWalker. I uncovered a strong signature indicative of a reactive stroma in 
tumors from patients with high depressive symptoms (Figure 24a and Table 7).  I 
then compared the top 200 genes from these tumors with gene expression data 
comparing microdissected CAFs and normal fibroblasts (GEO GSE40643), and 
found 22 genes that were common to the high depression score group and the 
CAFs, indicating that CAFs are indeed enriched during chronic adrenergic 
signaling  (Figure 21a and Table 8).  
CAFs are associated with worse overall survival in ovarian cancer with 
documented roles in inflammation, immune cell infiltration and metastasis. To 
validate the biological relevance of these findings, I used beta adrenergic 
receptor (ADRB) positive cell lines in orthotopic mouse models of both human 
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(Skov3-ip1 and HeyA8) and murine (ID8-ip1) epithelial ovarian cancer. These 
tumor models show increased tumor growth, metastasis and angiogenesis under 
restraint stress. I induced chronic stress by using a well-characterized physical-
restraint system in which animals are physically confined in a small chamber for 
2 hours every day for 21 days [101, 109]. In addition, restraint stress causes 
sustained elevations of NE in tumors [109]. In tumors obtained at necropsy, 
samples from mice exposed to chronic restraint stress had significantly greater 
numbers of intratumoral cells positive for the CAF marker, alpha smooth muscle 
actin (α-SMA), in all models (Skov3-ip1: 4.23-fold increase, p<0.05; HeyA8: 1.88-
fold increase, p<0.01; ID8-ip1 2.9-fold increase, p<0.05) (Figure 21b) [134]. 
Fibroblasts in tumors can also flank big vessels, and hence smooth muscle cells 
can also stain positive for α-SMA, we also co-stained for CD31 and α-SMA. The 
significantly higher α-SMA–positive signal in tumors from mice that underwent 
chronic stress than in controls was independent of CD31-positive cells, indicating 
that restraint stress induced an increase in the CAF phenotype (CD31-
independent a-SMA+ cells: 1.8-fold increase) (Figure 21c) [135, 160]. There was 
a time-dependent CAF phenotype which was more pronounced in mice stressed 
for 21 days than in those stressed for 7 days (Skov3-ip1: 2.1-fold increase, 
p<0.05; ID8-ip1 2.2-fold increase, p<0.05) (Figure 24d). In addition to α-SMA, 
other CAF markers such as fibroblast-activated protein (FAP), Platelet Derived 
Growth Factor Receptor-α and S100A4 are commonly used. I also evaluated 
another CAF marker, FAP and found a similar increase in its expression under 
restraint stress in Skov3-ip1 model (Figure 22b). CAFs are an integral part of 
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tumor microenvironment and CAFs were detected in primary as well as all 
metastatic sites in these preclinical models of ovarian cancer. The CAF content 
was increased by restraint stress compared to controls in the Skov3 model (2-
fold increase, p<0.05) in primary site and common places of ovarian cancer 
metastasis such as omentum, peritoneum, and mesentery (Figure 22c). All of this 
data shows adrenergic signaling can accelerate CAF induction within ovarian 
cancer tumors in patient and preclinical models.  
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Figure 21: Chronic stress accelerates induction of the cancer-associated 
fibroblast (CAF) phenotype in ovarian carcinoma 
 (a) Results from NetWalker analysis to identify networks of upregulated genes in 
ovarian cancer patients with high CES-D (i.e., depression) scores. (b) Expression 
of alpha–smooth muscle actin (α-SMA, a CAF marker) in micrographs of 
representative tumors from control and restraint-stressed mice in adrenergic 
79  
  
receptor–positive Skov3-ip1, HeyA8, and ID8-ip1 models. (c) Expression of α-
SMA and CD31 (blood vessel marker) in micrographs of representative Skov3-
ip1 tumors from control and stressed mice. (d) Expression of α-SMA in 
micrographs of representative tumors from mice subjected to short-term (7 days) 
or long-term (21 days) stress. Scale bars, 100µM, n=5/group for all data.  
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Figure 22: Restraint stress increases CAF content in primary as well as 
metastatic sites. 
 
 (a) Venn diagram showing comparison of genes that are upregulated 2-fold in 
tumor samples from ovarian cancer patients with a high depression (dep) score 
compared to those with a low depression score and in microdissected cancer-
associated fibroblasts (CAFs) compared to normal fibroblasts in primary ovarian 
cancer. FC, fold-change. (b) Expression of CAF marker fibroblast activated 
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protein (FAP) in micrographs of representative tumors from control and restraint-
stressed mice in the adrenergic-receptor positive Skov3-ip1 model. (c) 
Expression of CAF marker alpha–smooth muscle actin (α-SMA) in micrographs 
of representative normal tissues and matched metastatic tumors from the Skov3-
ip1 mouse model. Scale bars, 100µM, n=5/group for FAP data, n=3/group for 
metastatic data.   
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Annotation 
ID 
Functional 
Annotation 
Genes 
GO:0031012 extracellular 
matrix 
COL5A3, COL5A1, COL1A2, LGALS1, COL1A1, 
MMP11, PI3, SPARC, THBS1, COL8A1, COL8A2, 
CTGF, TIMP2, TNC, DCN, COL6A1, COL3A1, 
COL17A1, VWF, CTSD 
GO:0005578 proteinaceous 
extracellular 
matrix 
COL5A3, COL5A1, COL1A2, LGALS1, COL1A1, 
MMP11, PI3, SPARC, COL8A1, COL8A2, CTGF, 
TIMP2, TNC, DCN, COL6A1, COL3A1, COL17A1, 
VWF 
GO:0001568 blood vessel 
development 
COL5A1, COL1A2, COL1A1, ITGA5, THBS1, 
ANPEP, COL8A1, COL8A2, C5AR1, CTGF, 
TGFBR2, COL3A1, LYL1 
GO:0001944 vasculature 
development 
COL5A1, COL1A2, COL1A1, ITGA5, THBS1, 
ANPEP, COL8A1, COL8A2, C5AR1, CTGF, 
TGFBR2, COL3A1, LYL1 
GO:0044420 extracellular 
matrix part 
COL5A3, COL5A1, COL1A2, COL1A1, SPARC, 
COL8A1, COL8A2, TIMP2, TNC, DCN, COL6A1, 
COL3A1, COL17A1 
GO:0051707 response to 
other 
organism 
CCL8, ACTA2, CD14, LBP, PLA2G2A, GPX3, SOD2, 
CCL5, C5AR1, CXCL12, HCK, DCN, NFKBIA 
83  
  
GO:0031589 cell-substrate 
adhesion 
COL5A3, LGALS1, ITGA11, COL1A1, ITGB5, ITGA3, 
THBS1, ITGB2, COL8A1, CTGF, COL3A1, 
COL17A1, VWF 
GO:0007596 blood 
coagulation 
COL1A2, COL1A1, RAC2, ITGA5, ITGA3, SPARC, 
THBS1, ITGB2, TFPI, SLC16A3, PECAM1, COL3A1, 
VWF 
GO:0007599 hemostasis COL1A2, COL1A1, RAC2, ITGA5, ITGA3, SPARC, 
THBS1, ITGB2, TFPI, SLC16A3, PECAM1, COL3A1, 
VWF 
GO:0030247 polysaccharid
e binding 
COL5A3, COL5A1, SUSD2, CCL8, THBS1, CD14, 
ABP1, CTGF, TGFBR2, NCAN, DCN 
GO:0032403 protein 
complex 
binding 
COL5A1, ITGB5, ITGA5, THBS1, CTGF, TIMP2, 
HCLS1, COL3A1, VWF, NFKBIA, CTSB 
GO:0008544 epidermis 
development 
COL5A3, COL5A1, COL1A2, COL1A1, LTB, EVPL, 
KRT17, PPL, CTGF, COL3A1, COL17A1 
GO:0043062 extracellular 
structure 
organization 
COL5A3, COL5A1, COL1A2, COL1A1, MYH11, 
COL8A2, CTGF, TNC, NCAN, COL3A1 
GO:0019838 growth factor 
binding 
COL5A1, COL1A2, COL1A1, IGFBP3, THBS1, 
IGFBP4, CTGF, TGFBR2, COL6A1, COL3A1 
GO:0005539 glycosaminogl
ycan binding 
COL5A3, COL5A1, CCL8, THBS1, CD14, ABP1, 
CTGF, TGFBR2, NCAN, DCN 
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GO:0005581 collagen COL5A3, COL5A1, COL1A2, COL1A1, COL8A1, 
COL8A2, DCN, COL6A1, COL3A1, COL17A1 
GO:0006954 inflammatory 
response 
ALOX5AP, ALOX5, CCL8, THBS1, IGFBP4, CD14, 
ITGB2, LBP, PLA2G2A, CCL5 
GO:0007409 axonogenesis COL5A1, COL1A2, COL1A1, RAC2, ITGA5, MYH11, 
UCHL1, NCAN, COL6A1, COL3A1 
Table 7: Top networks upregulated in tumors from patients with high CES-D 
scores compared to those with low CES-D scores, with corresponding involved 
genes 
Affymetrix Symbol Patient Samples Gene array for CAFs 
202207_at ARL4C 3.05 3.03 
212077_at CALD1 2.12 2.27 
37892_at COL11A1 4.47 5.674 
201852_x_at COL3A1 2.15 4.399 
212489_at COL5A1 2.09 3.809 
221730_at COL5A2 2.33 4.267 
221541_at CRISPLD2 3.11 3.083 
201360_at CST3 2.04 2.065 
209101_at CTGF 4.52 2.773 
213274_s_at CTSB 2.12 2.691 
210764_s_at CYR61 2.34 2.305 
219454_at EGFL6 2.71 3.673 
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211719_x_at FN1 2.28 2.777 
211911_x_at HLA-B 2.15 2.27 
211990_at HLA-DPA1 2.35 2.561 
209312_x_at HLA-DRB1 2.62 2.445 
211634_x_at IGHM 2.12 2.326 
216560_x_at IGLC1 2.73 3.048 
210511_s_at INHBA 2.14 3.482 
203417_at MFAP2 2.08 2.52 
209596_at MXRA5 2.94 4.471 
201058_s_at MYL9 2.21 2.151 
202620_s_at PLOD2 2.14 2.562 
210809_s_at POSTN 2.88 4.933 
218723_s_at RGCC 2.03 2.767 
203889_at SCG5 4.31 2.185 
212667_at SPARC 2.07 2.984 
203083_at THBS2 2.09 2.568 
201147_s_at TIMP3 2.23 2.324 
215034_s_at TM4SF1 2.87 2.239 
202241_at TRIB1 2.43 2.374 
203868_s_at VCAM1 2.45 2.108 
211571_s_at VCAN 2.55 4.584 
Table 8: Genes common to GSE9116 and GDS40643, arranged alphabetically 
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4.2 Promotion of CAF phenotype by chronic adrenergic signaling  
There are 3 ADRB receptors with distinct expression patterns in tissue and 
varied biological functions. I first wanted to identify if this was due to direct effect 
of NE signaling in fibroblasts and to do this, I used the A2780 cells that are 
negative for all ADRB receptors. In this model, restraint stress has no effect on 
tumor growth or metastasis but if there are direct effects of NE signaling on 
fibroblasts, I hypothesized that there would be an increase in CAF content. There 
was no significant difference in α-SMA expression between tumors from control 
and restraint-stress groups (A2780: 1.1-fold change, p>0.05) (Figure 23a). The 
increase in CAF content during restraint stress was only seen in ADRB+ cells, 
indicating the important role of adrenergic signaling in tumor cells for driving the 
stress-induced CAF phenotype. 
Catecholamines such as norepinephrine, epinephrine can trigger signaling in 
tumor and other cell types with ADRB and ADRA receptors respectively [88]. 
Compared to epinephrine, most tumor effects are driven by norepinephrine and 
in patient tumors; depressive symptoms are associated with NE and not 
epinephrine. To further assess the roles of norepinephrine signaling as the 
primary catecholaminergic driver of the CAF phenotype under chronic stress, I 
assessed the expression of α-SMA after chronic restraint stress in tumors from 
adrenalectomized mice that had been injected with ID8-ip1 cells. In these 
animals, the adrenal glands were surgically removed and tumor cells were 
injected after the animal recovered. By adrenalectomy, we are eliminating the 
primary source of circulating epinephrine and norepinephrine which are adrenal 
87  
  
glands, but preserving the primary source of norepinephrine (which is released 
predominately from local peripheral nerves) [161]. The tumors from 
adrenalectomized mice had significant increases in α-SMA levels under restraint 
stress (2.5- and 3.1-fold increases over controls in sham surgery and 
adrenalectomy groups, respectively; p<0.05) (Figure 23b), implying a primary 
role of NE. To further define the role of adrenergic receptors downstream of 
adrenergic signaling, I used beta-blockers and agonists. Propranolol is an FDA-
approved beta-blocker for cancer and cardiovascular ailments that works by 
blocking all 3 ADRB receptors. Isoproterenol and terbutaline are broad and 
ADRB2-specific beta-agonists which can be given systemically to activate ADRB 
receptors. I first started by blocking all 3 ADRB using propranolol. I treated tumor 
bearing mice with PBS or propranolol, a nonspecific beta-blocker that blocks all 
downstream beta-adrenergic signaling in cells. Propranolol abrogated the stress-
mediated increases in α-SMA level in the HeyA8 model (PBS: 2.2-fold increases; 
p<0.05, propranolol: 0.87-fold change, p>0.05) (Figure 23c) and reduced gene 
expression of CAF markers in the Skov3-ip1 model (Figure 23c). Conversely, 
treatment of tumor bearing mice with either isoproterenol (non-specific beta 
agonist) or terbutaline (ADRB2-specific agonist) increased CAFs by 2.5 and 3.1-
fold, respectively in tumors (Figure 23d).  Since agonists and beta-blockers are 
not specific to tumor cells, and I wanted to see specifically the contribution of 
adrenergic-signaling in tumor cells, we used siRNA incorporated into DOPC 
nanoliposomes to silence ADRB2 in tumor cells. siRNA against human-specific 
ADRB2 was incorporated into DOPC nanoliposomes and given at 5 ug per 
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mouse biweekly by intraperitoneal injections. In the HeyA8 mouse model in 
which ADRB2 was silenced by siRNA incorporated into nanoliposomes, stress-
mediated increases in α-SMA expression were abrogated (Figure 23e).  
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Figure 23: Induction of the cancer-associated fibroblast (CAF) phenotype in 
ovarian carcinoma is due to the indirect effects of adrenergic signaling. 
  
  
 
(a) Expression of CAF marker alpha–smooth muscle actin (α-SMA) in 
micrographs of representative tumors from control and restraint-stressed mice in 
the adrenergic-receptor (ADRB)–negative A2780 (orthotopic) model. (b) 
Expression of α-SMA in micrographs of representative ID8 tumors from control 
and stressed mice that underwent adrenalectomy (Adrenal.) or sham surgery. (c) 
Expression of α-SMA in micrographs of representative HeyA8 tumors from 
control and stressed mice treated with the nonspecific beta-blocker propranolol 
or phosphate-buffered saline solution (PBS, controls). (d) ) Expression of α-SMA 
in micrographs of representative HeyA8 tumors from control and stressed mice 
treated with PBS (control), nonspecific beta-agonist isoproterenol, or ADRB2-
specific agonist terbutaline. € Expression of α-SMA in micrographs of 
representative HeyA8 tumors from control and stressed mice treated with control 
or ADRB2 siRNA loaded into nanoliposomal DOPC. Scale bars, 100µm, 
n=5/group for all data.  
  
91  
  
We also examined the consequences of tumor cell adrenergic stimulation for 
fibroblast activation in vitro.  We used NOF151, a normal fibroblast cell line that is 
derived from normal ovary and has been previously characterized [139]. Similar 
to fibroblasts in preclinical models, these cells have low expression of adrenergic 
receptors and therefore do not respond to direct NE treatment, as indicated by 
lack of increase in cAMP levels (Figures 24a and 24b). However NOF151 cells 
exposed to either control medium conditioned by untreated cancer cells, or 
medium conditioned by NE-treated cancer cells, we saw increased expression of 
CAF markers ACTA2, FAP, and S100A4 RNA and α-SMA protein (Figures 24c 
and 24d). Two characteristics of transformed fibroblasts in vitro are increased 
production of pro-inflammatory cytokines and increased migration [141, 142]. 
Conditioned medium from NE-treated cancer cells increased expression of pro-
inflammatory cytokines such as MCP1, CXCL1, MIF, GM-CSF, and G-CSF 
(Figure 24e) and migratory potential (Figure 24f) in NOF151 cells. Taken 
together, these results demonstrate that NE exposure induces tumor cells to 
express soluble factors that enhance activation of normal fibroblasts.  
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 (a) Expression of beta-adrenergic receptors (ADRB) in NOF151 normal 
Figure 24: Conditioned media from NE-treated cancer cells accelerate 
transformation of normal ovarian fibroblasts 
  
fibroblasts relative to ADRB-positive Skov3-ip1 cells. (b) ELISA for cAMP in 
NOF151 treated with norepinephrine (NE) for 15 or 30 min or not treated (NT). 
(c) Expression of CAF marker alpha–smooth muscle actin ( -SMA) in NOF151 
cells after exposure to medium conditioned by NE-treated Skov3-ip1 cells. (d) 
Expression of CAF markers ACTA2, S100A4, and FAP in NOF151 cells after 
exposure to medium conditioned by Skov3-ip1 cells treated with NE or NT. (e) 
Immunoblot multiplex assay for pro-inflammatory cytokines in NOF151 cells 
exposed to medium conditioned by NE-treated or NT Skov3-ip1 cells. (1: GCSF, 
2: GM-CSF, 3:IL1a, 4: CCL2, 5: MIF, 6: CCL3, 7: PAI1) (f) In vitro migratory 
potential of NOF151 cells toward serum-free medium (SFM), medium 
conditioned by untreated Skov3-ip1 cells, or medium conditioned by NE-treated 
SKov3-ip1 cells through 0.1% gelatin over 6 h was assessed by fixing and 
counting the number of cells migrated per high-power field. Scale bars, 100µM. 
Statistical significance was obtained using the 1-way ANOVA: *p < 0.05, **p < 
0.01, ***p<0.001. 
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Consistent with the adrenergic receptor specificity documented above in vivo, 
NOF151 cells exposed in vitro to medium from isoproterenol- or terbutaline-
treated cancer cells showed greater α-SMA induction than those exposed to 
medium conditioned by non-treated cells (Figure 25a). Conditioned medium from 
ADRB2-silenced cancer cells abrogated expression of CAF marker ACTA2 in 
NOF151 cells (Figure 25b).  
Figure 25:  Restraint stress increases α-SMA in an ADRB2-dependent manner 
 (a) Expression of CAF markers ACTA2, S100A4, and FAP in NOF151 cells 
exposed to serum-free medium (SFM) or to medium conditioned by Skov3-ip1 
cells that were untreated (NT) or treated with norepinephrine (NE), nonspecific 
beta-agonist isoproterenol (Iso), or ADRB2-specific agonist terbutaline (Terb). (b) 
ACTA2 expression in NOF151 treated with ADRB2 or control siRNA and 
conditioned with NT or NE-treated Skov3-ip1 cells. Scale bar, 100 m. S ta tis tica l 
significance was obtained using the 1-way ANOVA: *p < 0.05, **p < 0.01, 
***p<0.001. 
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4.3 Stromal effects of chronic stress 
I next wanted to study the biological consequences of fibroblast activation by 
chronic stress. To obtain an unbiased approach, I used NetWalker for gene 
expression analysis to identify upregulated networks in patient gene expression 
array from GSE9116 (Figure 26a). From this analysis and the results shown in 
Table 4, I identified that there was an increased collagen signature in tumors 
during chronic stress. Collagens in ovarian tumors have been shown to drive 
metastasis, impede immune cell infiltration and diminish chemotherapy efficacy. 
To assess collagen content in tumors, histological staining is primarily used 
including Masson’s Trichrome and Sirius. Masson Trichrome is used to identify 
connective tissue from cells in histological samples. This is a chromogenic, 
chemical based assay in which nuclei are stained black, connective tissue blue 
and cytoplasm stains pink. Sirius is another chromogenic assay that 
preferentially stains collagens 1 and 3. Masson trichrome staining and Sirius 
staining of Skov3-ip1 and HeyA8 tumors confirmed elevated collagen deposition 
after restraint stress in the in vivo mouse model (increase of 2.1-fold, p<0.05) 
(Figure 26b). Stress-mediated collagen deposition in tumors was largely 
abrogated by propranolol treatment in both models (1.64- and 1.01-fold increases 
over controls in PBS- and propranolol-treated groups, respectively; p=0.05 for 
PBS group) (Figure 26c).  Similarly, restraint stress–induced increases in 
collagen were also abrogated by ADRB2 silencing, as shown by both trichrome 
and Sirius staining (Figure 26d). Treating animals with the non-specific beta-
agonist or the ADRB2-specific agonist resulted in significant increases in tumoral 
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collagen (1.81- and 1.75-fold increases for isoproterenol- and terbutaline-treated 
groups, respectively, over PBS-treated controls; p<0.05) (Figure 26e).  
Figure 26: Adrenergic signaling increases collagen deposition and extracellular 
matrix formation in ovarian tumors. 
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(a) An unbiased network of genes differentially upregulated in tumor samples 
from high depression score and low depression score patients. (b) Expression of 
collagen identified by Masson trichrome staining in micrographs of representative 
Skov3-ip1 tumors from control and restraint-stressed mice. (c) Expression of 
collagen in representative Skov3-ip1 tumors from control and stressed mice 
treated with nonspecific beta-blocker propranolol or phosphate-buffered saline 
solution (PBS, controls). (d) Expression of collagen identified by Masson 
trichrome staining in micrographs of representative HeyA8 tumors from control 
and stressed mice treated with control or ADRB2 siRNA. (e) Expression of 
collagen identified by Masson trichrome staining in micrographs of representative 
HeyA8 tumors from control and stressed mice treated with PBS (control), 
nonspecific beta-agonist isoproterenol, or ADRB2-specific agonist terbutaline. 
(Scale bars, 100µM, n=5/group for all data.  
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Sirius stain is also a chromogenic stain more specific to collagens 1 and 3. Both 
of these collagens were identified to be elevated in chronic adrenergic signaling. 
Sirius staining showed collagens was significantly increased by 2-fold in both 
HeyA8 and Skov3 tumors under chronic restraint stress (figure 27a). Similar to 
Trichrome staining, Sirius stains showed adrenergic-mediated increases in 
collagens 1 and 2 were abrogated during systemic propranolol treatment (Figure 
27b). I also assessed expression levels of several collagens identified from the 
patient datasets using murine-specific primers to identify only stromal-based 
changes. Several genes involved in collagen synthesis were elevated in tumors 
from mice exposed to restraint stress, and these increases were also abrogated 
by propranolol (Figure 27c). Silencing ADRB2 in tumor cells using DOPC 
nanoliposomes also decreased collagen 1 and 3 in tumors (Figure 27d). In vitro, 
NOF151 normal fibroblasts exposed to medium conditioned by NE-treated 
cancer cells showed similar elevations in the same collagen genes (Figure 27e). 
However, NOF151 conditioned to ADRB2 silenced Skov3 cells did not show 
these elevations in collagen genes (Figure 27f). 
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Figure 27: Restraint stress increases collagen levels in tumors in an ADRB2 
dependent manner 
 (a) Expression of collagen detected by Sirius staining in micrographs of 
representative Skov3-ip1 and HeyA8 tumors from control and restraint-stressed 
mice. (b) Expression of collagen detected by Sirius staining on micrographs of 
representative HeyA8 tumors from control and stressed mice treated with 
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nonspecific beta-blocker propranolol or PBS. (c) Expression of collagen genes in 
Skov3-ip1 tumors from control and stressed mice treated with nonspecific beta-
blocker propranolol (Prop) or Saline. (d) Expression of collagen detected by 
Sirius staining in micrographs of representative HeyA8 tumors from control and 
stressed mice treated with control or ADRB2 siRNA. (e) Expression of collagen 
genes in NOF151 cells exposed to medium conditioned by untreated (NT) or 
norepinephrine (NE)-treated Skov3-ip1 cells. Scale bars, 100µM. (f) Expression 
of collagen genes in NOF151 cells exposed to medium conditioned by  untreated 
(NT) or norepinephrine (NE) and ADRB2 silenced Skov3 cells. Scale bars, 
100µM. Statistical significance was obtained using the 1-way ANOVA: *p < 0.05, 
**p < 0.01 compared to controls, p<0.05 compared to stress or NE-treated cells.  
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4.4 Induction of CAF phenotype by NE-mediated Inhibin, Beta A 
production  
My data demonstrates that cell contact between cancer cells and fibroblasts are 
not required for the NE-induced CAF phenotype. I hypothesized that cytokines, 
growth factors or other such extracellular factors were central to this 
phenomenon. Using a gene array dataset of Skov3-ip1 and HeyA8 cells treated 
with NE, we identified several potential genes that are induced by NE that could 
be mediators of this effect [101]. I also wanted to identify potential upstream 
regulators that are central to CAF activation in ovarian tumors. For this, I used 
Ingenuity Pathway Analysis (IPA) on gene arrays of microdissected CAFs and 
normal ovarian tissues to identify upstream regulators of CAFs [139]. Combining 
the gene array and systems-based analyses, I identified IL6 (interleukin 6) and 
INBHA (Inhibin, Beta A) as factors that could potentially drive CAF expression 
(Figure 28a) [101]. IL6 is an important proinflammatory cytokine that is potently 
induced upon NE treatment in ovarian cancer cells. In addition, elevated plasma 
levels of IL6 are also associated with ovarian cancer patients who show 
depressive symptoms. Inhibin, Beta A is also elevated in plasma of ovarian 
cancer patients. However, there is no knowledge of NE driving Inhibin, Beta A 
levels in cells. To identify which gene is more likely to be the mediator, I used 
coexpression analysis of genes using Oncomine. Oncomine is a web-based 
portal with publicly available datasets such as TCGA that enables users to do 
survival, expression and other analysis. I used Oncomine to analyze co-
expression of INHBA and IL6 with genes upregulated in ovarian cancer samples 
102  
  
included in The Cancer Genome Atlas (TCGA). INHBA, but not IL6, was highly 
correlated with stroma-related genes that were upregulated in both patient 
datasets (Tables 9 and 10). Therefore, I focused primarily on INHBA for 
subsequent experiments. 
In the GEO data set GSE9116, I noted INHBA mRNA levels were increased 2.14 
fold in tumors from patients with high depression scores (Figure 28b). In the in 
vivo preclinical models, restraint stress significantly increased Inhibin, Beta A 
levels in Skov3-ip1 and HeyA8 tumors (2.3- and 3.1-fold increases over non-
stress controls, respectively, p<0.05) (Figure 28c). Treatment with propranolol 
abrogated the increases in tumoral INHBA indicating that blocking beta-
adrenergic receptors can block this effect (Figure 28d). 
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Figure 28: Induction of cancer-associated fibroblasts (CAF) in ovarian carcinoma 
is mediated by Inhibin, Beta A downstream of norepinephrine. 
(a) Schema used for Ingenuity Pathway Analysis (IPA) of three different ovarian 
carcinoma cell lines to identify upstream regulators of CAF induction. (b) 
Validation of Inhibin, Beta A levels in tumors from patients with high depression 
scores and low depression scores; data were obtained from GEODATASET 
GSE9116. (c) Expression of Inhibin, Beta A in micrographs of representative 
Skov3-ip1 and HeyA8 tumors from control and restraint-stressed mice. (d) 
Expression of Inhibin, Beta A in micrographs of representative HeyA8 tumors 
from control and stressed mice treated with nonspecific beta-blocker propranolol 
or phosphate-buffered saline solution (PBS, control). Scale bars, 100µM, 
n=5/group for all data.  104  
  
Gene 
Symbol Reporter ID Correlation 
INHBA 210511_s_at 1 
THBS2 203083_at 0.90183127 
COL11A1 204320_at 0.8865286 
COL11A1 37892_at 0.8865286 
FAP 209955_s_at 0.8479447 
CTSK 202450_s_at 0.8479447 
VCAN 211571_s_at 0.8479447 
SPARC 212667_at 0.8177246 
AEBP1 201792_at 0.8177246 
COL1A2 202403_s_at 0.8177246 
COL6A3 201438_at 0.8177246 
COL3A1 201852_x_at 0.8177246 
COL5A1 212489_at 0.8177246 
COL5A2 221730_at 0.8177246 
MMP2 201069_at 0.81008625 
SNAI2 213139_at 0.8011878 
FBN1 202765_s_at 0.8011878 
FN1 211719_x_at 0.7849791 
COL10A1 217428_s_at 0.7731993 
- 205941_s_at 0.7731993 
CDH11 207172_s_at 0.7619725 
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DCN 209335_at 0.7619725 
LUM 201744_s_at 0.7619725 
SERPINF1 202283_at 0.731467 
CRISPLD2 221541_at 0.72007775 
ASPN 219087_at 0.72007775 
POSTN 210809_s_at 0.72007775 
TMEM158 213338_at 0.7155617 
OLFML2B 213125_at 0.7155617 
ADAM12 213790_at 0.7155617 
ADAM12 202952_s_at 0.7155617 
NTM 222020_s_at 0.7155617 
ECM1 209365_s_at 0.7155617 
LRRC15 213909_at 0.7155617 
MMP11 203876_s_at 0.7155617 
COPZ2 219561_at 0.71121013 
PCOLCE 202465_at 0.6899231 
THBS1 201108_s_at 0.68605226 
GLT8D2 221447_s_at 0.68131775 
- 221019_s_at 0.68131775 
MMP19 204575_s_at 0.67816544 
COL6A1 212091_s_at 0.6591419 
COL6A2 209156_s_at 0.6591419 
ANGPTL2 213004_at 0.6519295 
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ITGA5 201389_at 0.6519295 
LOXL2 202998_s_at 0.6519295 
RAB31 217762_s_at 0.6445346 
PLAU 205479_s_at 0.6445346 
VCAM1 203868_s_at 0.6445346 
LPPR4 213496_at 0.6307415 
ETV1 221911_at 0.6307415 
COL16A1 204345_at 0.6217892 
BGN 213905_x_at 0.6217892 
C1QTNF3 220988_s_at 0.6091054 
TIMP3 201147_s_at 0.6091054 
- 214927_at 0.6091054 
ITGBL1 205422_s_at 0.6091054 
EPYC 206439_at 0.6091054 
PRRX1 205991_s_at 0.60363436 
EDNRA 216235_s_at 0.60363436 
Table 9: Gene co-expression with INHBA in TCGA ovarian cancer samples 
(highlighted probes common with Table 4) 
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Gene 
Symbol Reporter ID Correlation 
IL6 205207_at 1 
HBEGF 203821_at 0.533625 
CH25H 206932_at 0.492976 
THBD 203887_s_at 0.492976 
NR4A3 209959_at 0.492976 
GEM 204472_at 0.492976 
RGS2 202388_at 0.492976 
SLC2A14 216236_s_at 0.391042 
SLC2A3 202497_x_at 0.391042 
SGK1 201739_at 0.334213 
PTGS2 204748_at 0.304811 
NR4A2 204621_s_at 0.293695 
DUSP2 204794_at 0.293695 
BTG2 201236_s_at 0.293695 
ZEB1 208078_s_at 0.293695 
RHOB 212099_at 0.293695 
JUN 201464_x_at 0.293695 
IER2 202081_at 0.293695 
JUNB 201473_at 0.293695 
KLF6 208961_s_at 0.293695 
GADD45B 207574_s_at 0.293695 
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PPP1R15A 37028_at 0.293695 
EGR2 205249_at 0.293695 
CYR61 201289_at 0.293695 
CTGF 209101_at 0.293695 
ATF3 202672_s_at 0.293695 
DUSP1 201044_x_at 0.293695 
EGR3 206115_at 0.293695 
NR4A1 202340_x_at 0.293695 
FOSB 202768_at 0.293695 
ZFP36 201531_at 0.293695 
EGR1 201694_s_at 0.293695 
FOS 209189_at 0.293695 
CEBPD 203973_s_at 0.293695 
EDN1 218995_s_at 0.293695 
C10orf10 209182_s_at 0.293695 
GADD45A 203725_at 0.293695 
KLF10 202393_s_at 0.293695 
BHLHE40 201169_s_at 0.293695 
PLK3 204958_at 0.293695 
DUSP5 209457_at 0.293695 
LIF 205266_at 0.293695 
MAFF 205193_at 0.293695 
IER3 201631_s_at 0.293695 
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C8orf4 218541_s_at 0.293695 
Table 10: Gene co-expression with IL6 in TCGA ovarian cancer samples 
(highlighted genes common with Table 4) 
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In vitro, treatment of Skov3-ip1 cancer cells with NE significantly induced INHBA 
expression, and pretreatment of HeyA8 cells with propranolol or ADRB2-
antagonist butoxamine abrogated this effect (Figures 29a and 29b). Silencing 
ADRB2 using siRNA decreased INHBA expression in Skov3 cells after NE 
treatment (Figure 29c). NE can activate several transcription factors but primarily 
CREB1, Nf-kB and AP-1. Since Inhibin, Beta A gene was induced 3 hours after 
NE treatment I decided to start by looking at transcriptional activation of INHBA. 
TRANSFAC is a curated database for eukaryotic transcription factors, which 
provides promoter region and binding sequences for all genes. Using this, I 
identified CREB as potential transcription factor driving INHBA expression. Using 
TRANSFAC, I identified and designed primers specific to the promoter regions of 
INHBA where CREB1 binds. Chromatin immunoprecipitation analysis showed 
that NE increased CREB binding to the INHBA promoter 4-fold compared to 
normal IgG controls (Figure 29d). Silencing CREB1 using siRNA also reduced 
NE-induced INHBA expression (Figure 29e). Conditioned medium from CREB1-
silenced Skov3-ip1 cells also failed to increase ACTA2 expression in NOF151 
cells, demonstrating the importance of Inhibin, Beta A in driving the NE-mediated 
CAF phenotype (Figure 29f). 
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Figure 29: INHBA expression in tumor cells is mediated by ADRB2 and CREB 
 (a) Expression of INHBA in Skov3-ip1 cells after no treatment (NT) or treatment 
with norepinephrine (NE) with or without propranolol or ADRB2-specific blocker 
butoxamine. (b) Concentration of Inhibin, Beta A in HeyA8 cells after no 
treatment or treatment with NE with or without propranolol, or butoxamine. (c) 
Effect of silencing ADRB2 on INHBA expression in Skov3 cells not treated or 
treated with NE. (d) Chromatin immunoprecipitation analysis for CREB binding to 112  
  
the INHBA promoter in Skov3-ip1 cells not treated or treated with NE. (e) Effect 
of silencing CREB on INHBA expression in Skov3 cells not treated or treated with 
NE.(f) Effect of medium conditioned by CREB1 siRNA– or control siRNA–treated 
cells not treated or treated with NE on CAF marker ACTA2 expression in 
NOF151 cells Scale bars, 100µM. Statistical significance was obtained using the 
1-way ANOVA: *p < 0.05, **p < 0.01, ***p<0.001. 
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I then wanted to check if silencing INHBA in cancer cells also prevent induction 
of CAF-phenotype. I used several sequences for INHBA and validated 
knockdown using ELISA and qRT-PCR. Conditioned medium from INHBA-
silenced cancer cells failed to increase ACTA2 levels in NOF151 (Figure 30a-
30b). Functionally, NOF151 fibroblasts exposed to medium conditioned by 
INHBA-silenced Skov3-ip1 cells also showed decreased levels of the same 
collagens that were elevated in the patient tumor samples (Figure 30c and 30d). 
Taken together, these results indicate that NE drives the CAF phenotype via an 
ADRB2-CREB-INHBA axis.  
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Figure 30: Conditioned media from INHBA-silenced tumor cells decrease CAF-
phenotype and collagens in NOF151 
(a) Validation of multiple sequences of INHBA siRNA in HeyA8 cells not treated 
(NT) or treated with norepinephrine (NE). (b) Concentration of Inhibin, Beta A in 
HeyA8 cells after INHBA was silenced via siRNA sequence 2 and no treatment 
or treatment with NE. (c) Effect of conditioned medium from INHBA siRNA– or 
control siRNA–treated Skov3 cells on expression of CAF marker ACTA2 in 
untreated or NE-treated NOF151 cells. (d) Effect of conditioned medium from 
ADRB2 siRNA– or INHBA siRNA– NE-treated Skov3 cells on collagen 
expression in NOF151 cells. Statistical significance was obtained using the 1-
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way ANOVA: *p < 0.05, **p < 0.01 compared to control, p<0.05 , ††p<0.01 
compared to NE-treated cells.  
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I then wanted to silence INHBA in vivo to study stromal changes more directly in 
preclinical models. I used a nanoliposomal (1,2-dioleoyl-sn-glycero-3-
phosphatidylcholine [DOPC]) system to silence INHBA in the tumor cells in the 
HeyA8 model. DOPC-based liposomes have been used to deliver siRNA and 
microRNAs to tumor cells efficiently in multiple models of cancer. Animals are 
treated with siRNA twice a week by IP injection. Restraint stress was induced 
using the physical restraint system described in the methods. Silencing INHBA 
decreased both tumor growth and metastasis (Figure 31a). Knockdown of INHBA 
was validated by both RNA expression using human-specific sequences (Figure 
31b). More importantly, silencing Inhibin, Beta A decreased restraint stress–
mediated increases in the CAF phenotype at both protein and mRNA levels 
(Figure 31c and 31d). Silencing INHBA in HeyA8 tumor cells decreased collagen 
deposition in vivo and also reduced levels of the collagens that were significantly 
elevated in the patient tumor samples (Figure 31e and Figure 31f).  
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Figure 31: Effects of silencing INHBA in cancer cells 
(a) Effects of silencing INHBA in vivo on tumor weight and tumor in nodules in 
orthotopic HeyA8 tumor-bearing mice subjected or not subjected (control) to daily 
restraint stress and treated twice per week with either control siRNA or INHBA 
siRNA. (b) Validation of knockdown of INHBA by qRT-PCR. (c) Expression of 
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CAF marker alpha–smooth muscle actin (α-SMA) in micrographs of 
representative HeyA8 tumors from control and stressed mice treated with control 
or INHBA siRNA (d) Expression of ACTA2 after INHBA silencing. (e) Expression 
of collagen identified by Masson trichrome staining in micrographs of 
representative HeyA8 tumors from control and stressed mice treated with control 
or INHBA siRNA. (f) Expression of collagens after INHBA silencing. Scale bars, 
100µM, n=5/group for all data. Statistical significance was obtained using the 1-
way ANOVA: *p < 0.05, **p < 0.01 compared to siControl-no stress, †p<0.05, 
††p<0.01 compared to siControl-Stress. 
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I then focused on downstream signaling in NOF151 cells. Inhibin, Beta A 
functions via ACVR2a or ACVR2b receptors and downstream activation of 
Smad2/3 proteins. I started by staining the preclinical samples for both the 
receptors. Tumor stroma was weakly positive for ACVR2a and positive for 
ACVR2b (figure 32a). In vitro, I used NOF151 to silence both these receptors 
and studied changes in CAF and collagen genes. Silencing ACVR2b, not 
ACVR2a in NOF151 cells; abrogated changes in both ACTA2 and collagen 
expression mediated by NE-conditioned media (figure 32b). Further downstream 
of the receptors, SMAD proteins are activated by members of the TGFb pathway. 
Exposure of fibroblasts to media conditioned by NE-treated cancer cells resulted 
in a 3-fold increase in p-SMAD2 compared to media from non-treated cells 
(figure 32c).  
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Figure 32: Role of Activin receptor in driving collagens 
(a) Expression of ACVR2a and ACVR2b in ovarian tumor stroma. (d) Effect of 
NE-conditioned media after silencing ACVR2a and ACVR2b in NOF151 cells on 
ACTA2 and collagen expression. (c) Effect of NE-conditioned media on 
downstream SMAD2 activation in NOF151 cells.  Statistical significance was 
obtained using the 1-way ANOVA: *p < 0.05, **p < 0.01 compared to siControl. 
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To check if INHBA affected survival outcomes, I analyzed the TCGA dataset 
using KMPlot. In 522 patients with high-grade serous ovarian cancer, primary 
tumors were evaluated for INHBA (210511_s_at) expression levels. All stages, 
TP53 status were included in the analysis with auto select of the best cutoff. 
Elevated INHBA expression was associated with significantly shorter overall 
survival in the TCGA ovarian cancer dataset (lower expression: 48.07 months, 
high expression: 39.57 months) (Figure 33a). Elevated INHBA expression was 
also associated with significantly progression-free survival in the TCGA ovarian 
cancer dataset (lower expression: 20.63 months, high expression: 15.63 months) 
(Figure 33a). Using Oncomine, I also assessed stage-wise expression of INHBA 
in ovarian cancer and there was an increase in expression associated with 
advanced stage (figure 33b).  
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Figure 33: INHBA in ovarian cancer is associated with worse PFS and OS. 
(a) Kaplan-Meier plots for overall survival (left) and progression-free survival 
(right) in patients with ovarian cancer, based on expression level of INHBA. Data 
were extracted from The Cancer Genome Atlas database. (b) Expression of 
INHBA with stage (TCGA data). 
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4.5 Adrenergic signaling–mediated CAFs modulate collagen in 
breast and colorectal cancers 
Clinical and preclinical data have shown that chronic stress can exacerbate 
colorectal, breast, and prostate cancers in addition to ovarian cancer [88]. I 
wanted to study which other tumor types also show induction of the CAF 
phenotype during chronic adrenergic signaling. In both colon and breast cancers 
greater numbers of CAFs are associated with shorter survival, increased 
metastasis, and therapy resistance [130, 134, 162]. To determine whether our 
findings apply to other cancer types, we examined both clinical data and in 
vivo tumor samples from breast and colon cancer models. In mouse models 
generated from ADRB-positive RKO colon cancer cells or GILM2 breast cancer 
cells, α-SMA levels were significantly increased by restraint stress (2.2- and 3.4-
fold increases for RKO and GILM2, respectively; p<0.05) (Figure 34a). There 
were concomitant increases in collagen in the tumors of mice subjected to 
restraint stress (1.7- and 2.1-fold increases for RKO and GILM2, respectively; 
p<0.05) (Figure 34b). Expression data from TCGA showed that INHBA levels are 
higher in tumors than in normal tissue (Figure 34c). Most intriguingly, analysis of 
genes that were co-expressed with INHBA in TCGA colorectal and ovarian 
cancers revealed significant overlap with the prominent CAF phenotype observed 
in ovarian cancer, and collagen patterns in these tumors were comparable to 
those in ovarian cancer (Tables 11 and 12). To further show the importance of 
chronic adrenergic signaling in promoting ECM- and CAF-related genes, we 
analyzed an independent set of renal carcinoma samples from patients with 
124  
  
known CES-D scores for collagens and CAF markers; the results show there is 
higher levels of gene expression for collagens, INHBA and ACTA2 in patients 
with higher depressive symptoms (Figure 34d). 
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Figure 34: Restraint stress induces cancer-associated fibroblasts (CAFs) in 
colon, breast, and renal cancer models. 
(a) Expression of CAF marker alpha–smooth muscle actin (α-SMA) in 
micrographs of representative tumors from control and restraint-stressed mice in 
adrenergic-receptor positive RKO (colon cancer) and GILM2 (breast cancer) 
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models. (b) Expression of collagen identified by Masson trichrome staining in 
micrographs of representative RKO and GILM2 tumors from control and stressed 
mice.  (C) Pan-cancer INHBA expression from TCGA data. d)) Clinical validation 
of adrenergic-mediated CAF-phenotype in renal cell carcinoma samples using 
qRT-PCR p-values as indicated (total samples=9, 4 in CESD<4 and 5 in 
CESD>21).  Scale bars, 100µM, Means ± SEM, n=5/group for RKO data and 
n=3/group for GILM2 data.   
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Breast Cancer 
INHBA A_23_P122922 1 
PPAPDC1A A_24_P810284 0.847718 
COL11A1 A_23_P11806 0.847718 
KIF26B A_23_P63541 0.804722 
MMP11 A_23_P57417 0.79355 
COL10A1 A_23_P214140 0.79355 
GJB2 A_23_P407042 0.77325 
FN1 A_24_P85539 0.756792 
MMP13 A_23_P138931 0.713044 
HSD17B6 A_23_P25030 0.704811 
SPOCK1 A_24_P354689 0.675556 
COL12A1 A_24_P291814 0.675556 
CTHRC1 A_23_P111886 0.675556 
COL3A1 A_24_P935491 0.675556 
ASPN NM_017680_2_2198 0.675556 
AEBP1 A_23_P145918 0.675556 
NOX4 A_23_P47147 0.675556 
COL8A1 A_23_P69030 0.675556 
COL1A2 A_24_P265274 0.675556 
LOC651721 A_24_P282266 0.675556 
WISP1 NKI_NM_003882 0.675556 
LOC100128844 A_32_P141365 0.675556 
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P4HA3 A_23_P127956 0.675556 
TMEM90B NM_024893_1_1555 0.675556 
LRRC15 A_24_P827032 0.675556 
CDH11 A_23_P152305 0.675556 
POSTN A_24_P347411 0.675556 
ADAM12 A_23_P202327 0.675556 
COL6A3 NM_004369_1_9684 0.675556 
VCAN A_23_P144959 0.675556 
COL1A1 A_23_P207521 0.675556 
COL5A2 A_23_P10391 0.675556 
COL5A1 A_23_P158590 0.675556 
THBS2 A_23_P253652 0.675556 
FAP A_23_P56746 0.675556 
TNFSF4 A_23_P126836 0.655745 
LOC401097 A_23_P305243 0.655745 
CILP2 A_23_P108238 0.642901 
CORIN A_23_P81131 0.634304 
TLL2 A_23_P404778 0.610464 
ERMN A_23_P102017 0.609356 
PLAU A_23_P24103 0.609356 
SULF1 A_23_P43165 0.609356 
KIAA1199 A_23_P324754 0.609356 
GREM1 A_23_P432945 0.571732 
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COMP A_23_P90436 0.565048 
PPEF1 A_23_P125505 0.543588 
GRM8 A_32_P8221 0.543588 
MATN3 NM_002381_2_2496 0.527919 
C20orf103 A_23_P40294 0.527919 
GRP A_23_P101134 0.527919 
ST6GAL2 A_32_P126157 0.527919 
RGS4 A_23_P200737 0.510739 
LOC285548 A_24_P892494 0.50405 
NKX3-2 A_23_P386254 0.50405 
Table 11: Gene co-expression with INHBA in TCGA breastl cancer samples 
(highlighted genes common with ovarian cancer) 
Colorectal Cancer 
INHBA A_23_P122922 1 
COL11A1 NM_080629_1_6174 0.889562 
ADAM12 NM_003474_2_4854 0.826843 
NOX4 A_23_P47148 0.826843 
CTHRC1 A_23_P111886 0.826843 
FAP A_23_P56746 0.826843 
COL10A1 A_23_P214140 0.826843 
COL5A2 A_32_P218731 0.811893 
WISP1 NKI_NM_003882 0.809216 
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PDPN A_23_P201322 0.809216 
COL8A1 A_23_P69030 0.786018 
ITGA11 A_23_P206022 0.786018 
P4HA3 A_23_P127956 0.786018 
SULF1 A_23_P43165 0.786018 
THBS2 A_23_P253651 0.786018 
PPAPDC1A A_24_P810284 0.786018 
COL1A1 A_23_P207521 0.786018 
COL12A1 A_24_P291810 0.786018 
COL6A3 NM_004369_1_9860 0.786018 
COL1A2 A_23_P255244 0.786018 
SPARC A_23_P7642 0.786018 
ZNF469 A_23_P335080 0.786018 
CDH11 A_23_P152305 0.786018 
KAL1 A_23_P429948 0.754175 
LOC651721 A_24_P282266 0.744667 
HS3ST3A1 A_23_P66523 0.72371 
POSTN A_23_P205111 0.72371 
LOX NM_002317_3_1867 0.72371 
TWIST1 A_23_P71067 0.715534 
ST6GALNAC5 A_23_P33093 0.698786 
LUM A_32_P28664 0.698786 
TMEM90B A_24_P190504 0.698786 
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FBN1 A_24_P152553 0.698786 
ANTXR1 A_24_P131522 0.698786 
NTM A_23_P84060 0.698786 
SPOCK1 A_23_P81598 0.698786 
HTRA3 A_23_P395438 0.698786 
TNFSF4 A_23_P126833 0.672474 
MXRA5 A_24_P282355 0.662766 
ADAMTS6 A_23_P213319 0.632247 
KIF26B A_23_P63541 0.632247 
CNIH3 A_23_P384044 0.625946 
SHISA2 A_32_P55236 0.625946 
MMP11 A_23_P57417 0.625946 
PPEF1 A_23_P125503 0.625946 
MFAP2 A_23_P1027 0.625946 
LRRC15 A_24_P827037 0.616798 
HMCN1 A_23_P148991 0.616798 
CRISPLD1 A_23_P59958 0.616798 
COMP A_23_P90430 0.616798 
ITGBL1 A_23_P113777 0.616798 
SFRP4 A_23_P215320 0.616798 
KCNE4 A_23_P392574 0.604307 
DIO2 A_23_P48736 0.581334 
CLEC5A A_23_P304356 0.550313 
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SLN A_23_P150343 0.550313 
C5orf46 A_23_P19176 0.550313 
FGF1 A_23_P213330 0.550313 
OLR1 A_24_P124624 0.550313 
SPP1 A_23_P7311 0.550313 
MMP13 A_23_P138931 0.54776 
ALPK2 A_23_P15876 0.54776 
PRRX1 A_23_P502731 0.54776 
FN1 NM_002026_1_7942 0.541192 
DKK2 A_23_P155847 0.52731 
GRP A_23_P101134 0.52731 
EDNRA A_24_P217572 0.521915 
Table 12: Gene co-expression with INHBA in TCGA colorectal cancer samples 
(highlighted genes common with ovarian cancer) 
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5 Summary and Future Directions 
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5.1 Summary 
A growing number of studies have shown a role of elevated adrenergic signaling 
in driving tumor progression and adversely affecting survival. Epidemiological 
studies, preclinical and in vitro studies in ovarian, lung, prostate, breast, renal 
and colon cancers have shown norepinephrine can activate pro-survival and 
metastatic networks on cancer cells that result in increased tumor growth and 
decreased survival [88].  
All the studies studying adrenergic influences focused on a particular aspect of 
tumor progression, but in this study we start with an unbiased analysis to identify 
novel pathways that are influenced by norepinephrine. Using clinical data from 
patients with known biobehavioral profiles it enabled us to identify pathways that 
included both cancer cells and stromal components.  
Tumor microenvironment is a complex milieu with multiple host cells, including 
macrophages, endothelial cells, infiltrating immune cells, and cancer associated 
fibroblasts. Data showing effects on stroma is limited and was pursued further in 
this study. In this dissertation, I focused on the effect and mechanism by which 
catecholamine signaling in drives stromal changes in the microenvironment in 
ovarian cancer (figure 35). Using gene expression data patients with known 
depressive scores, I first identified a prominent association between depressive 
symptoms and CAF phenotype. Cancer associated fibroblasts are important in 
ovarian cancer, and have functions in driving metastasis and 
immunosuppression [133]. Therefore studying the role of chronic stress in driving 
CAFs in tumors can further explain some of the documented effects on tumor 135  
  
progression. Several genes that were elevated such as THBS2, ACTA2, and 
SPARC are also established CAF markers. Elevated gene networks in patients 
with high depressive symptoms include those associated with proteinaceous 
extracellular matrix, collagens, and epidermis development primarily various 
collagens. I then validated this CAF phenotype using both in vitro and in vivo   
studies. Staining for a-SMA which is a prominent CAF marker, there are 
significantly increased levels in Skov3, HeyA8 and ID8-VEGF in vivo models. In 
vitro, normal ovarian fibroblasts that were exposed to NE-conditioned media from 
cancer cells showed accelerated CAF induction. To identify the mechanism 
leading to CAF-phenotype, I utilized both bioinformatic and molecular biology 
approaches, and identified a novel mechanism of fibroblast activation triggered 
by Inhibin, Beta A production by tumor cells in response to sustained adrenergic 
stimulation. Inhibin, Beta A is a member of the TGF-b pathway that has direct 
role on cancer cells in promoting tumor growth, but no data exists showing a role 
in CAF phenotype. In TCGA clinical samples, INHBA was also highly correlated 
with genes that were identified to be elevated in patients with high depressive 
scores. Inhibin, Beta A production by cancer cells after NE treatment was 
triggered by an ADRB2-CREB axis and silencing ADRB2 or CREB using siRNA 
abrogated NE-induced Inhibin, Beta A production. Additionally, fibroblasts 
exposed to conditioned media treated with from ADRB2 and CREB silenced cells 
also did not show increases in CAF genes such as ACTA2, S100A4 and FAP.  
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Figure 35: Summary 
To determine the biological consequences of adrenergic-mediated CAF 
phenotype, I focused on the extracellular matrix and collagen proteins. Using 
histological Trichrome staining, I identified levels of several collagens such as 
COL3A1, COL5A1, COL5A2 and COL11A1 are driven by downstream Inhibin, 
Beta A-signaling in CAFs and were elevated during adrenergic signaling. When 
animals were treated with beta-blockers, stress-related collagen increases in 
tissue was eliminated. I also silenced Inhibin, Beta A in cancer cells using 
liposomal nanoparticles containing siRNA, and this abrogated all collagen and 
CAF changes in tumors. 
To extend our findings to other cancers, we also studied colon and breast cancer 
models using RKO and GILM2 in vivo models respectively. Chronic stress 
significantly increased a-SMA, Inhibin, Beta A and collagen levels similar to 
ovarian cancer. In addition, in both cases INHBA was also associated with high 137  
  
co-expression of collagen and CAF genes. Using an independent dataset of 
renal cell carcinoma patients with known depression scores, there was a trend 
towards increased ACTA2, INHBA and collagen genes associated with increased 
CESD scores.   
Work done in this project extends our understanding on how catecholamines can 
affect the tumor microenvironment. For the first time, we have shown that INHBA 
can be induced by NE stimulation in cancer cells, and this can induce a 
prominent CAF phenotype in ovarian cancer. Association studies have shown 
INHBA closely tracks with collagen genes in cancer, and we found similar results 
using TCGA in ovarian, colon and breast cancers. However, our studies differ 
from those published in that we show the association is casual and is driven by 
INHBA inducing collagen genes. We provide evidence the silencing INHBA can 
have profound effects on tumor stroma especially CAFs.  
Although the principal effect is still on tumor stroma, the effect is still mediated by 
norepinephrine acting on cancer cells. Blocking ADRB signaling in tumor cells 
caused decreases in stromal content and CAF phenotype in several cancer 
types. With increasing number of studies that are focusing on the role of chronic 
stress in exacerbating diseases including cancer, we provide another motivation 
to combine beta blockers with conventional therapy. Beta blockers are approved 
by the FDA for heart disease (and infantile hemangioma) and are in clinical trials 
for ovarian cancer. Propranolol is well tolerated and has very few side effects, 
and provides another very targetable drug to block stromal changes.    
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5.2 Future Directions 
Chronic stress and NE-mediated ADRB2 and CREB signaling in cancer cells is 
important for increasing angiogenesis, tumor invasion and inflammation. In 
cardiac tissues, NE can promote fibrosis by increasing proliferation of primary 
cardiac fibroblasts in a TGFb1-dependent pathway [163]. CREB driven Inhibin, 
Beta A signaling in hippocampus is neuroprotective by reducing excitotoxic 
neuronal damage [164]. Inhibin, Beta A is a member of the TGF-β pathway and 
is overexpressed in prostate, ovarian, colorectal, and breast cancers [151, 165, 
166]. Elevated serum and plasma levels of Inhibin, Beta A have been reported in 
patients with metastatic ovarian, breast, and prostate cancers [151, 165, 166]. In 
our study, silencing Inhibin, Beta A in tumor cells reduced the levels of 
adrenergic stimulus induced CAFs and collagen significantly. Although co-
expression of collagen genes with INHBA has been reported in some cancers, 
the functional relationships have not been well understood [167]. 
Several studies have identified the direct role of NE in driving molecular changes 
in tumor cells but influences on stroma have been limited to natural killer cells, 
macrophage infiltration and angiogenesis [88]. Effects of adrenergic signaling on 
CAFs and extracellular matrix provide a previously unrecognized dimension that 
could have therapeutic implications. CAFs are the major part of tumor stroma 
and provide tumor cells with vital cues for invasion by remodeling the 
microenvironment through synthesis and deposition of collagens and producing 
pro-inflammatory cytokines and other growth factors[133].  Targeting stroma can 
lead to several clinical benefits including increased immune cell infiltration and 
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decreased metastasis Collagens in the extracellular matrix can engage integrins 
on tumor cells, impede T-cell infiltration and facilitate invasion and metastasis. 
Importantly, collagens identified in our study (e.g., COL5A1, COL11A1 and 
COL1A1) are also associated with increased metastasis and poor overall survival 
in ovarian cancer [168].  
5.3 Study Impact 
Cancer diagnosis and treatment are extremely stressful events for patients and 
families, and American Psychological Association also frequency reports that 
chronic stress events in individuals are on the rise.  Hence, studying the interplay 
between stress hormones and their effects on tumor biology is becoming 
increasingly important. To our knowledge, this is the first report that studies 
adrenergic influences on tumor growth in a completely unbiased manner. 
Although the role of chronic stress and psychological parameters are shown to 
exacerbate cancer have been shown in several cancers, thoughtful 
pharmacological and biobehavioral interventions to prevent this are few. 
Biobehavorial interventions for cancer patients has been studied since 1970. 
Some of the interventions that have been tried and proven to yield success 
include regular therapy, relaxation training, social adjustment and also health 
behaviour such as exercise, dietary modifications and strategies for symptoms 
management (e.g., nausea, sleep deprivation). Biobehavioral interventions have 
several limitations, including but not limited to high costs, treatment dropout, and 
lower adherence to interventions. Hence, beta-blockers which are FDA-approved 
with well tolerated side effects would be the ideal to treat chronic stress in cancer 
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patients. In infantile hemangioma, beta blockers are the standard of care with 
Beta blockers are currently being tested in clinical trials in combination with 
chemotherapy in ovarian cancer. Understanding the various modes by which 
catecholamines will affect tumor microenvironment will enable us to design novel 
drug combinations with beta blockers.  Emerging data from molecular 
underpinnings that drive NE-induced tumor growth can be harnessed further to 
effectively combine therapeutic interventions (such as beta blockers) and 
behavioural interventions with novel antagonists and inhibitors. There is data to 
show that beta blockers can combine well with NSAIDs such as etodolac and 
aspirin by blocking direct effects of NE and downstream inflammation signaling. 
As studies continue to support the many molecular mechanisms that drive NE-
mediated tumor growth, several targeted therapies (such as bevacizumab or 
immunotherapy) can be combined in large scale randomized studies to study 
clinical benefits. 
Inhibin, Beta A was identified in the study to be the most important extracellular 
factor produced by cancer cells that can drive CAF phenotype in tumors. To our 
knowledge, this is the first report to show that Inhibin, Beta A is necessary for 
increased collagen levels in CAFs and may be an important biomarker for tumor 
progression. This was not limited to ovarian cancer, but similar changes in NE-
induced Inhibin, Beta A increased collagen levels in breast and colorectal 
preclinical models. High depressive scores was also associated with high 
expression of Inhibin, Beta A and collagens in renal cell carcinoma. Several 
studies have focused on targeting Inhibin, Beta A to prevent cancer cachexia, but 
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our results demonstrate important roles in modulating the tumor stroma [169-171] 
that can be targeted to prevent potential tumor metastatic and increase T-cell 
infiltration. 
STM434, a humanized decoy receptor for activin receptor, is currently in a 
clinical trial for treating patients with metastatic and chemotherapy resistant 
ovarian cancer (NCT02262455). Single agent STM 434 showed an acceptable 
safety profile in patients with advanced solid tumors and early evidence of clinical 
activity. Beta-blockers are associated with survival benefit in several cancers and 
our results suggest combining beta-blockers with novel targeting agents such as 
Inhibin, Beta A decoy receptors in treatment regimens. Disruption of interactions 
between cancer cells and stress hormones or cancer cells and fibroblasts may 
improve outcomes of cancer patients. As the importance of Inhibin, Beta A and 
collagens in driving cancers emerge, several therapies targeting them can be 
combined with beta-blockers to improve patient survival in ovarian, colon, breast 
and renal cell cancers.  
  
142  
  
6 References 
[1] H. Selye, Stress and Disease, Science, 122 (1955) 625-631. 
[2] H. Selye, Stress and the general adaptation syndrome, British medical 
journal, 1 (1950) 1383-1392. 
[3] H. Selye, A syndrome produced by diverse nocuous agents. 1936, The 
Journal of neuropsychiatry and clinical neurosciences, 10 (1998) 230-231. 
[4] H. Selye, The general adaptation syndrome and the diseases of adaptation, 
The Journal of allergy, 17 (1946) 231; 289; 358. 
[5] H. Selye, The general adaptation syndrome and the diseases of adaptation, 
The Journal of allergy, 17 (1946) 231 passim. 
[6] H. Selye, The general adaptation syndrome and the diseases of adaptation, 
The Journal of clinical endocrinology and metabolism, 6 (1946) 117-230. 
[7] H. Selye, Stress without distress, 1st ed., Lippincott, Philadelphia,, 1974. 
[8] A. Baum, Stress, intrusive imagery, and chronic distress, Health psychology : 
official journal of the Division of Health Psychology, American Psychological 
Association, 9 (1990) 653-675. 
[9] M. Sapolsky Robert, Why zebras don't get ulcers : a guide to stress, stress 
related diseases, and coping, W.H. Freeman, New York, 1994. 
[10] M.H. Antoni, S.K. Lutgendorf, S.W. Cole, F.S. Dhabhar, S.E. Sephton, P.G. 
McDonald, M. Stefanek, A.K. Sood, The influence of bio-behavioural factors on 
tumour biology: pathways and mechanisms, Nat Rev Cancer, 6 (2006) 240-248. 
[11] S.K. Lutgendorf, K. DeGeest, L. Dahmoush, D. Farley, F. Penedo, D. 
Bender, M. Goodheart, T.E. Buekers, L. Mendez, G. Krueger, L. Clevenger, D.M. 
143  
  
Lubaroff, A.K. Sood, S.W. Cole, Social isolation is associated with elevated 
tumor norepinephrine in ovarian carcinoma patients, Brain Behav Immun, 25 
(2011) 250-255. 
[12] B.S. McEwen, Physiology and neurobiology of stress and adaptation: 
Central role of the brain, Physiol Rev, 87 (2007) 873-904. 
[13] B.S. McEwen, Allostasis and allostatic load: implications for 
neuropsychopharmacology, Neuropsychopharmacology, 22 (2000) 108-124. 
[14] E.J. Hermans, M.J.A.G. Henckens, M. Joels, G. Fernandez, Dynamic 
adaptation of large-scale brain networks in response to acute stressors, Trends 
Neurosci, 37 (2014) 304-314. 
[15] P. Payne, P.A. Levine, M.A. Crane-Godreau, Somatic Experiencing: using 
interoception and proprioception as core elements of trauma therapy (vol 6, pg 
93, 2015), Front Psychol, 6 (2015). 
[16] S.W. Cole, A.K. Sood, Molecular Pathways: Beta-Adrenergic Signaling in 
Cancer, Clin Cancer Res, 18 (2012) 1201-1206. 
[17] X.M. Zhang, D.T. Odom, S.H. Koo, M.D. Conkright, G. Canettieri, J. Best, 
H.M. Chen, R. Jenner, E. Herbolsheimer, E. Jacobsen, S. Kadam, J.R. Ecker, B. 
Emerson, J.B. Hogenesch, T. Unterman, R.A. Young, M. Montminy, Genome-
wide analysis of cAMP-response element binding protein occupancy, 
phosphorylation, and target gene activation in human tissues, P Natl Acad Sci 
USA, 102 (2005) 4459-4464. 
144  
  
[18] R.H. Oakley, J.A. Cidlowski, The biology of the glucocorticoid receptor: new 
signaling mechanisms in health and disease, The Journal of allergy and clinical 
immunology, 132 (2013) 1033-1044. 
[19] M. Kadmiel, J.A. Cidlowski, Glucocorticoid receptor signaling in health and 
disease, Trends in pharmacological sciences, 34 (2013) 518-530. 
[20] N. Mercado, A. Hakim, Y. Kobayashi, S. Meah, O.S. Usmani, K.F. Chung, 
P.J. Barnes, K. Ito, Restoration of corticosteroid sensitivity by p38 mitogen 
activated protein kinase inhibition in peripheral blood mononuclear cells from 
severe asthma, PloS one, 7 (2012) e41582. 
[21] A.M. Goldminz, S.C. Au, N. Kim, A.B. Gottlieb, P.F. Lizzul, NF-kappaB: an 
essential transcription factor in psoriasis, Journal of dermatological science, 69 
(2013) 89-94. 
[22] U. Baschant, N.E. Lane, J. Tuckermann, The multiple facets of 
glucocorticoid action in rheumatoid arthritis, Nature reviews. Rheumatology, 8 
(2012) 645-655. 
[23] M.N. Silverman, E.M. Sternberg, Glucocorticoid regulation of inflammation 
and its functional correlates: from HPA axis to glucocorticoid receptor 
dysfunction, Annals of the New York Academy of Sciences, 1261 (2012) 55-63. 
[24] M. Zen, M. Canova, C. Campana, S. Bettio, L. Nalotto, M. Rampudda, R. 
Ramonda, L. Iaccarino, A. Doria, The kaleidoscope of glucorticoid effects on 
immune system, Autoimmunity reviews, 10 (2011) 305-310. 
[25] Y. Cao, I.K. Bender, A.K. Konstantinidis, S.C. Shin, C.M. Jewell, J.A. 
Cidlowski, R.P. Schleimer, N.Z. Lu, Glucocorticoid receptor translational isoforms 
145  
  
underlie maturational stage-specific glucocorticoid sensitivities of dendritic cells 
in mice and humans, Blood, 121 (2013) 1553-1562. 
[26] V.H. Nargund, Effects of psychological stress on male fertility, Nat Rev Urol, 
12 (2015) 373-382. 
[27] R. Glaser, R.C. MacCallum, B.F. Laskowski, W.B. Malarkey, J.F. Sheridan, 
J.K. Kiecolt-Glaser, Evidence for a shift in the Th-1 to Th-2 cytokine response 
associated with chronic stress and aging, J Gerontol A Biol Sci Med Sci, 56 
(2001) M477-482. 
[28] J.K. Kiecolt-Glaser, L. McGuire, T.F. Robles, R. Glaser, Emotions, morbidity, 
and mortality: new perspectives from psychoneuroimmunology, Annu Rev 
Psychol, 53 (2002) 83-107. 
[29] S.K. Lutgendorf, E.S. Costanzo, Psychoneuroimmunology and health 
psychology: an integrative model, Brain Behav Immun, 17 (2003) 225-232. 
[30] S.K. Lutgendorf, D. Russell, P. Ullrich, T.B. Harris, R. Wallace, Religious 
participation, interleukin-6, and mortality in older adults, Health Psychol, 23 
(2004) 465-475. 
[31] M. Groeschel, B. Braam, Connecting chronic and recurrent stress to 
vascular dysfunction: no relaxed role for the renin-angiotensin system, Am J 
Physiol-Renal, 300 (2011) F1-F10. 
[32] E. Charmandari, C. Tsigos, G. Chrousos, Endocrinology of the stress 
response, Annu Rev Physiol, 67 (2005) 259-284. 
[33] R.H. Belmaker, G. Agam, Mechanisms of disease: Major depressive 
disorder, New Engl J Med, 358 (2008) 55-68. 
146  
  
[34] D.G. Blazer, R.C. Kessler, K.A. Mcgonagle, M.S. Swartz, The Prevalence 
and Distribution of Major Depression in a National Community Sample - the 
National Comorbidity Survey, Am J Psychiat, 151 (1994) 979-986. 
[35] L.S. Radloff, The CES-D Scale, Applied Psychological Measurement, 1 
(1977) 385-401. 
[36] R.G. Knight, S. Williams, R. McGee, S. Olaman, Psychometric properties of 
the Centre for Epidemiologic Studies Depression Scale (CES-D) in a sample of 
women in middle life, Behav Res Ther, 35 (1997) 373-380. 
[37] C.L.C. Taylor, H. Badr, J.H. Lee, F. Fossella, K. Pisters, E.R. Gritz, L. 
Schover, Lung Cancer Patients and Their Spouses: Psychological and 
Relationship Functioning Within 1 Month of Treatment Initiation, Ann Behav Med, 
36 (2008) 129-140. 
[38] S.E. Ward, G. Viergutz, D. Tormey, J. deMuth, A. Paulen, Patients' reactions 
to completion of adjuvant breast cancer therapy, Nursing research, 41 (1992) 
362-366. 
[39] E.R. Gritz, D.K. Wellisch, J. Siau, H.J. Wang, Long-term effects of testicular 
cancer on marital relationships, Psychosomatics, 31 (1990) 301-312. 
[40] D. Hann, K. Winter, P. Jacobsen, Measurement of depressive symptoms in 
cancer patients: Evaluation of the center for epidemiological studies depression 
scale (Ces-d), Journal of Psychosomatic Research, 46 (1999) 437-443. 
[41] T.Y. Huang, S.S. Tworoger, J.L. Hecht, M.S. Rice, A.K. Sood, L.D. 
Kubzansky, E.M. Poole, Association of Ovarian Tumor beta(2)-Adrenergic 
147  
  
Receptor Status with Ovarian Cancer Risk Factors and Survival, Cancer Epidem 
Biomar, 25 (2016) 1587-1594. 
[42] A.S. Nagaraja, N.C. Sadaoui, P.L. Dorniak, S.K. Lutgendorf, A.K. Sood, 
SnapShot: Stress and Disease, Cell Metab, 23 (2016) 388-388 e381. 
[43] C. Zoccali, F. Mallamaci, S. Parlongo, S. Cutrupi, F.A. Benedetto, G. Tripepi, 
G. Bonanno, F. Rapisarda, P. Fatuzzo, G. Seminara, A. Cataliotti, B. Stancanelli, 
L.S. Malatino, Plasma norepinephrine predicts survival and incident 
cardiovascular events in patients with end-stage renal disease, Circulation, 105 
(2002) 1354-1359. 
[44] R.D. Ross, S.R. Daniels, D.C. Schwartz, D.W. Hannon, R. Shukla, S. 
Kaplan, Plasma norepinephrine levels in infants and children with congestive 
heart failure, Am J Cardiol, 59 (1987) 911-914. 
[45] R.J. Cody, K.W. Franklin, J. Kluger, J.H. Laragh, Sympathetic 
responsiveness and plasma norepinephrine during therapy of chronic congestive 
heart failure with captopril, The American journal of medicine, 72 (1982) 791-797. 
[46] J.A. Thomas, B.H. Marks, Plasma norepinephrine in congestive heart failure, 
Am J Cardiol, 41 (1978) 233-243. 
[47] S. Golbidi, J.C. Frisbee, I. Laher, Chronic stress impacts the cardiovascular 
system: animal models and clinical outcomes, American journal of physiology. 
Heart and circulatory physiology, 308 (2015) H1476-1498. 
[48] S.A. Atlas, The renin-angiotensin aldosterone system: pathophysiological 
role and pharmacologic inhibition, Journal of managed care pharmacy : JMCP, 
13 (2007) 9-20. 
148  
  
[49] K.F. Adams, Jr., Pathophysiologic role of the renin-angiotensin-aldosterone 
and sympathetic nervous systems in heart failure, American journal of health-
system pharmacy : AJHP : official journal of the American Society of Health-
System Pharmacists, 61 Suppl 2 (2004) S4-13. 
[50] R.J. Cody, The sympathetic nervous system and the renin-angiotensin-
aldosterone system in cardiovascular disease, Am J Cardiol, 80 (1997) 9J-14J. 
[51] T. Zhang, Y. Zhai, Y. Chen, Z. Zhou, J. Yang, H. Liu, Effects of emotional 
and physiological stress on plaque instability in apolipoprotein E knockout mice, 
Journal of physiology and biochemistry, 67 (2011) 401-413. 
[52] H.S. Lett, J.A. Blumenthal, M.A. Babyak, A. Sherwood, T. Strauman, C. 
Robins, M.F. Newman, Depression as a risk factor for coronary artery disease: 
Evidence, mechanisms, and treatment, Psychosomatic medicine, 66 (2004) 305-
315. 
[53] M.J. Zellweger, R.H. Osterwalder, W. Langewitz, M.E. Pfisterer, Coronary 
artery disease and depression, European heart journal, 25 (2004) 3-9. 
[54] R.M. Carney, M.W. Rich, A. Tevelde, J. Saini, K. Clark, K.E. Freedland, The 
Relationship between Heart-Rate, Heart-Rate Variability and Depression in 
Patients with Coronary-Artery Disease, Journal of Psychosomatic Research, 32 
(1988) 159-164. 
[55] A. Steptoe, M. Kivimaki, Stress and cardiovascular disease, Nat Rev Cardiol, 
9 (2012) 360-370. 
[56] A.R. Lyon, P.S.C. Rees, S. Prasad, P.A. Poole-Wilson, S.E. Harding, Stress 
(Takotsubo) cardiomyopathy - a novel pathophysiological hypothesis to explain 
149  
  
catecholamine-induced acute myocardial stunning, Nat Clin Pract Card, 5 (2008) 
22-29. 
[57] Y.J. Akashi, D.S. Goldstein, G. Barbaro, T. Ueyama, Takotsubo 
Cardiomyopathy A New Form of Acute, Reversible Heart Failure, Circulation, 118 
(2008) 2754-2762. 
[58] J.P. Godbout, R. Glaser, Stress-Induced Immune Dysregulation: Implications 
for Wound Healing, Infectious Disease and Cancer, J Neuroimmune Pharm, 1 
(2006) 421-427. 
[59] R. Glaser, J. Kiecolt-Glaser, How stress damages immune system and 
health, Discovery medicine, 5 (2005) 165-169. 
[60] R. Glaser, J.K. Kiecolt-Glaser, Stress-induced immune dysfunction: 
implications for health, Nature reviews. Immunology, 5 (2005) 243-251. 
[61] G. Hubner, M. Brauchle, H. Smola, M. Madlener, R. Fassler, S. Werner, 
Differential regulation of pro-inflammatory cytokines during wound healing in 
normal and glucocorticoid-treated mice, Cytokine, 8 (1996) 548-556. 
[62] D.A. Padgett, P.T. Marucha, J.F. Sheridan, Restraint stress slows cutaneous 
wound healing in mice, Brain, behavior, and immunity, 12 (1998) 64-73. 
[63] J.K. Kiecolt-Glaser, R. Glaser, E.C. Shuttleworth, C.S. Dyer, P. Ogrocki, C.E. 
Speicher, Chronic stress and immunity in family caregivers of Alzheimer's 
disease victims, Psychosomatic medicine, 49 (1987) 523-535. 
[64] J.K. Kiecolt-Glaser, R. Glaser, S. Gravenstein, W.B. Malarkey, J. Sheridan, 
Chronic stress alters the immune response to influenza virus vaccine in older 
adults, Proc Natl Acad Sci U S A, 93 (1996) 3043-3047. 
150  
  
[65] R. Glaser, J.K. Kiecolt-Glaser, R.H. Bonneau, W. Malarkey, S. Kennedy, J. 
Hughes, Stress-induced modulation of the immune response to recombinant 
hepatitis B vaccine, Psychosomatic medicine, 54 (1992) 22-29. 
[66] A.V. Kusnecov, L.J. Grota, S.G. Schmidt, R.H. Bonneau, J.F. Sheridan, R. 
Glaser, J.A. Moynihan, Decreased herpes simplex viral immunity and enhanced 
pathogenesis following stressor administration in mice, Journal of 
neuroimmunology, 38 (1992) 129-137. 
[67] D.A. Padgett, J.F. Sheridan, J. Dorne, G.G. Berntson, J. Candelora, R. 
Glaser, Social stress and the reactivation of latent herpes simplex virus type 1, 
Proc Natl Acad Sci U S A, 95 (1998) 7231-7235. 
[68] M. Irwin, T. Patterson, T.L. Smith, C. Caldwell, S.A. Brown, J.C. Gillin, I. 
Grant, Reduction of immune function in life stress and depression, Biol 
Psychiatry, 27 (1990) 22-30. 
[69] S. Ben-Eliyahu, G.G. Page, R. Yirmiya, G. Shakhar, Evidence that stress 
and surgical interventions promote tumor development by suppressing natural 
killer cell activity, International journal of cancer, 80 (1999) 880-888. 
[70] J.E. Mawdsley, D.S. Rampton, Psychological stress in IBD: New insights into 
pathogenic and therapeutic implications, Gut, 54 (2005) 1481-1491. 
[71] B.L. Bonaz, C.N. Bernstein, Brain-Gut Interactions in Inflammatory Bowel 
Disease, Gastroenterology, 144 (2013) 36-49. 
[72] S. Cohen, D.A.J. Tyrrell, A.P. Smith, Psychological Stress and Susceptibility 
to the Common Cold, New Engl J Med, 325 (1991) 606-612. 
151  
  
[73] S.W. Cole, B.D. Naliboff, M.E. Kemeny, M.P. Griswold, J.L. Fahey, J.A. 
Zack, Impaired response to HAART in HIV-infected individuals with high 
autonomic nervous system activity, P Natl Acad Sci USA, 98 (2001) 12695-
12700. 
[74] S.W. Cole, Y.D. Korin, J.L. Fahey, J.A. Zack, Norepinephrine accelerates 
HIV replication via protein kinase A-dependent effects on cytokine production, J 
Immunol, 161 (1998) 610-616. 
[75] W.C. Koff, M.A. Dunegan, Neuroendocrine Hormones Suppress 
Macrophage-Mediated Lysis of Herpes-Simplex Virus-Infected Cells, J Immunol, 
136 (1986) 705-709. 
[76] J. Sacher, J. Neumann, T. Funfstuck, A. Soliman, A. Villringer, M.L. 
Schroeter, Mapping the depressed brain: A meta-analysis of structural and 
functional alterations in major depressive disorder, J Affect Disorders, 140 (2012) 
142-148. 
[77] M. Ye, T.L. Yang, P. Qing, X. Lei, J. Qiu, G.Y. Liu, Changes of Functional 
Brain Networks in Major Depressive Disorder: A Graph Theoretical Analysis of 
Resting-State fMRI, PloS one, 10 (2015). 
[78] A.L. Chirita, V. Gheorman, D. Bondari, I. Rogoveanu, Current understanding 
of the neurobiology of major depressive disorder, Rom J Morphol Embryo, 56 
(2015) 651-658. 
[79] C. Strobel, S. Hunt, R. Sullivan, J.Y. Sun, P. Sah, Emotional regulation of 
pain: the role of noradrenaline in the amygdala, Sci China Life Sci, 57 (2014) 
384-390. 
152  
  
[80] R.J. Smith, G. Aston-Jones, Noradrenergic transmission in the extended 
amygdala: role in increased drug-seeking and relapse during protracted drug 
abstinence, Brain Struct Funct, 213 (2008) 43-61. 
[81] E.J. Kim, B. Pellman, J.J. Kim, Stress effects on the hippocampus: a critical 
review, Learn Memory, 22 (2015) 411-416. 
[82] J.D. Bremner, P. Randall, T.M. Scott, R.A. Bronen, J.P. Seibyl, S.M. 
Southwick, R.C. Delaney, G. Mccarthy, D.S. Charney, R.B. Innis, Mri-Based 
Measurement of Hippocampal Volume in Patients with Combat-Related 
Posttraumatic-Stress-Disorder, Am J Psychiat, 152 (1995) 973-981. 
[83] T.J. Shors, E. Dryver, Effect of Stress and Long-Term Potentiation (Ltp) on 
Subsequent Ltp and the Theta-Burst Response in the Dentate Gyrus, Brain 
research, 666 (1994) 232-238. 
[84] J. Grandjean, D. Azzinnari, A. Seuwen, H. Sigrist, E. Seifritz, C.R. Pryce, M. 
Rudin, Chronic psychosocial stress in mice leads to changes in brain functional 
connectivity and metabolite levels comparable to human depression, 
Neuroimage, 142 (2016) 544-552. 
[85] S.K. Lutgendorf, K. DeGeest, C.Y. Sung, J.M. Arevalo, F. Penedo, J. Lucci, 
3rd, M. Goodheart, D. Lubaroff, D.M. Farley, A.K. Sood, S.W. Cole, Depression, 
social support, and beta-adrenergic transcription control in human ovarian 
cancer, Brain, behavior, and immunity, 23 (2009) 176-183. 
[86] L. Cohen, S.W. Cole, A.K. Sood, S. Prinsloo, C. Kirschbaum, J.M. Arevalo, 
N.B. Jennings, S. Scott, L. Vence, Q. Wei, D. Kentor, L. Radvanyi, N. Tannir, E. 
Jonasch, P. Tamboli, L. Pisters, Depressive symptoms and cortisol rhythmicity 
153  
  
predict survival in patients with renal cell carcinoma: role of inflammatory 
signaling, PloS one, 7 (2012) e42324. 
[87] E.I. Obeid, S.D. Conzen, The role of adrenergic signaling in breast cancer 
biology, Cancer biomarkers : section A of Disease markers, 13 (2013) 161-169. 
[88] S.W. Cole, A.S. Nagaraja, S.K. Lutgendorf, P.A. Green, A.K. Sood, 
Sympathetic nervous system regulation of the tumour microenvironment, Nature 
reviews. Cancer, 15 (2015) 563-572. 
[89] G. Bennett, T.A. Badger, Depression in men with prostate cancer, Oncology 
nursing forum, 32 (2005) 545-556. 
[90] D.R. Sullivan, C.W. Forsberg, L. Ganzini, D.H. Au, M.K. Gould, D. 
Provenzale, C.G. Slatore, Longitudinal Changes in Depression Symptoms and 
Survival Among Patients With Lung Cancer: A National Cohort Assessment, 
Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology, 34 (2016) 3984-3991. 
[91] K. Albrecht, H. Droll, J.M. Giesler, D. Nashan, F. Meiss, K. Reuter, Self-
efficacy for coping with cancer in melanoma patients: its association with physical 
fatigue and depression, Psycho-oncology, 22 (2013) 1972-1978. 
[92] A.D. Boyd, M. Riba, Depression and pancreatic cancer, Journal of the 
National Comprehensive Cancer Network : JNCCN, 5 (2007) 113-116. 
[93] E.J. Shakin, J. Holland, Depression and pancreatic cancer, Journal of pain 
and symptom management, 3 (1988) 194-198. 
154  
  
[94] E.S. Costanzo, S.K. Lutgendorf, A.K. Sood, B. Anderson, J. Sorosky, D.M. 
Lubaroff, Psychosocial factors and interleukin-6 among women with advanced 
ovarian cancer, Cancer, 104 (2005) 305-313. 
[95] A.S. Nagaraja, N.C. Sadaoui, S.K. Lutgendorf, L.M. Ramondetta, A.K. Sood, 
beta-blockers: a new role in cancer chemotherapy?, Expert opinion on 
investigational drugs, 22 (2013) 1359-1363. 
[96] Z.J. Shang, K. Liu, D.F. Liang, Expression of beta(2)-adrenergic receptor in 
oral squamous cell carcinoma, J Oral Pathol Med, 38 (2009) 371-376. 
[97] H.H. Grytli, M.W. Fagerland, S.D. Fossa, K.A. Tasken, Association Between 
Use of beta-Blockers and Prostate Cancer-Specific Survival: A Cohort Study of 
3561 Prostate Cancer Patients with High-Risk or Metastatic Disease, Eur Urol, 
65 (2014) 635-641. 
[98] T.I. Barron, R.M. Connolly, L. Sharp, K. Bennett, K. Visvanathan, Beta 
Blockers and Breast Cancer Mortality: A Population-Based Study, Journal of 
Clinical Oncology, 29 (2011) 2635-2644. 
[99] D.G. Powe, M.J. Voss, K.S. Zanker, H.O. Habashy, A.R. Green, I.O. Ellis, F. 
Entschladen, Beta-Blocker Drug Therapy Reduces Secondary Cancer Formation 
in Breast Cancer and Improves Cancer Specific Survival, Oncotarget, 1 (2010) 
628-638. 
[100] C. Leaute-Labreze, E. Dumas de la Roque, T. Hubiche, F. Boralevi, J.B. 
Thambo, A. Taieb, Propranolol for severe hemangiomas of infancy, The New 
England journal of medicine, 358 (2008) 2649-2651. 
155  
  
[101] G.N. Armaiz-Pena, J.K. Allen, A. Cruz, R.L. Stone, A.M. Nick, Y.G. Lin, L.Y. 
Han, L.S. Mangala, G.J. Villares, P. Vivas-Mejia, C. Rodriguez-Aguayo, A.S. 
Nagaraja, K.M. Gharpure, Z. Wu, R.D. English, K.V. Soman, M.M. Shahzad, M. 
Zigler, M.T. Deavers, A. Zien, T.G. Soldatos, D.B. Jackson, J.E. Wiktorowicz, M. 
Torres-Lugo, T. Young, K. De Geest, G.E. Gallick, M. Bar-Eli, G. Lopez-
Berestein, S.W. Cole, G.E. Lopez, S.K. Lutgendorf, A.K. Sood, Src activation by 
beta-adrenoreceptors is a key switch for tumour metastasis, Nature 
communications, 4 (2013) 1403. 
[102] J.M. Deussing, Animal models of depression, Drug Discovery Today: 
Disease Models, 3 (2006) 375-383. 
[103] A.N. Saul, T.M. Oberyszyn, C. Daugherty, D. Kusewitt, S. Jones, S. Jewell, 
W.B. Malarkey, A. Lehman, S. Lemeshow, F.S. Dhabhar, Chronic stress and 
susceptibility to skin cancer, Journal of the National Cancer Institute, 97 (2005) 
1760-1767. 
[104] N. Suhail, N. Bilal, S. Hasan, A. Ahmad, G.M. Ashraf, N. Banu, Chronic 
unpredictable stress (CUS) enhances the carcinogenic potential of 7,12-
dimethylbenz(a)anthracene (DMBA) and accelerates the onset of tumor 
development in Swiss albino mice, Cell stress & chaperones, 20 (2015) 1023-
1036. 
[105] C. Magnon, S.J. Hall, J. Lin, X.N. Xue, L. Gerber, S.J. Freedland, P.S. 
Frenette, Autonomic Nerve Development Contributes to Prostate Cancer 
Progression, Science, 341 (2013) 143-+. 
156  
  
[106] S. Hassan, Y. Karpova, D. Baiz, D. Yancey, A. Pullikuth, A. Flores, T. 
Register, J.M. Cline, R. D'Agostino, Jr., N. Danial, S.R. Datta, G. Kulik, 
Behavioral stress accelerates prostate cancer development in mice, The Journal 
of clinical investigation, 123 (2013) 874-886. 
[107] G.N. Armaiz-Pena, S.W. Cole, S.K. Lutgendorf, A.K. Sood, Neuroendocrine 
influences on cancer progression, Brain Behavior and Immunity, 30 (2013) S19-
S25. 
[108] G.N. Armaiz-Pena, S.K. Lutgendorf, S.W. Cole, A.K. Sood, Neuroendocrine 
modulation of cancer progression, Brain Behavior and Immunity, 23 (2009) 10-
15. 
[109] P.H. Thaker, L.Y. Han, A.A. Kamat, J.M. Arevalo, R. Takahashi, C. Lu, N.B. 
Jennings, G. Armaiz-Pena, J.A. Bankson, M. Ravoori, W.M. Merritt, Y.G. Lin, 
L.S. Mangala, T.J. Kim, R.L. Coleman, C.N. Landen, Y. Li, E. Felix, A.M. 
Sanguino, R.A. Newman, M. Lloyd, D.M. Gershenson, V. Kundra, G. Lopez-
Berestein, S.K. Lutgendorf, S.W. Cole, A.K. Sood, Chronic stress promotes 
tumor growth and angiogenesis in a mouse model of ovarian carcinoma, Nature 
medicine, 12 (2006) 939-944. 
[110] A.K. Sood, G.N. Armaiz-Pena, J. Halder, A.M. Nick, R.L. Stone, W. Hu, 
A.R. Carroll, W.A. Spannuth, M.T. Deavers, J.K. Allen, L.Y. Han, A.A. Kamat, 
M.M. Shahzad, B.W. McIntyre, C.M. Diaz-Montero, N.B. Jennings, Y.G. Lin, 
W.M. Merritt, K. DeGeest, P.E. Vivas-Mejia, G. Lopez-Berestein, M.D. Schaller, 
S.W. Cole, S.K. Lutgendorf, Adrenergic modulation of focal adhesion kinase 
157  
  
protects human ovarian cancer cells from anoikis, The Journal of clinical 
investigation, 120 (2010) 1515-1523. 
[111] K. Masur, B. Niggemann, K.S. Zanker, F. Entschladen, Norepinephrine-
induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers, 
Cancer Res, 61 (2001) 2866-2869. 
[112] X.Y. Huang, H.C. Wang, Z. Yuan, J. Huang, Q. Zheng, Norepinephrine 
stimulates pancreatic cancer cell proliferation, migration and invasion via beta-
adrenergic receptor-dependent activation of P38/MAPK pathway, Hepato-
gastroenterology, 59 (2012) 889-893. 
[113] A.K. Sood, R. Bhatty, A.A. Kamat, C.N. Landen, L. Han, P.H. Thaker, Y. Li, 
D.M. Gershenson, S. Lutgendorf, S.W. Cole, Stress hormone-mediated invasion 
of ovarian cancer cells, Clinical cancer research : an official journal of the 
American Association for Cancer Research, 12 (2006) 369-375. 
[114] E.V. Yang, S.J. Kim, E.L. Donovan, M. Chen, A.C. Gross, J.I. Webster 
Marketon, S.H. Barsky, R. Glaser, Norepinephrine upregulates VEGF, IL-8, and 
IL-6 expression in human melanoma tumor cell lines: implications for stress-
related enhancement of tumor progression, Brain, behavior, and immunity, 23 
(2009) 267-275. 
[115] A.S. Nagaraja, P.L. Dorniak, N.C. Sadaoui, Y. Kang, T. Lin, G. Armaiz-
Pena, S.Y. Wu, R. Rupaimoole, J.K. Allen, K.M. Gharpure, S. Pradeep, B. Zand, 
R.A. Previs, J.M. Hansen, C. Ivan, C. Rodriguez-Aguayo, P. Yang, G. Lopez-
Berestein, S.K. Lutgendorf, S.W. Cole, A.K. Sood, Sustained adrenergic 
158  
  
signaling leads to increased metastasis in ovarian cancer via increased PGE2 
synthesis, Oncogene, 35 (2016) 2390-2397. 
[116] Y. Kang, A.S. Nagaraja, G.N. Armaiz-Pena, P.L. Dorniak, W. Hu, R. 
Rupaimoole, T. Liu, K.M. Gharpure, R.A. Previs, J.M. Hansen, C. Rodriguez-
Aguayo, C. Ivan, P. Ram, V. Sehgal, G. Lopez-Berestein, S.K. Lutgendorf, S.W. 
Cole, A.K. Sood, Adrenergic Stimulation of DUSP1 Impairs Chemotherapy 
Response in Ovarian Cancer, Clinical cancer research : an official journal of the 
American Association for Cancer Research, 22 (2016) 1713-1724. 
[117] J. Liu, G.H. Deng, J. Zhang, Y. Wang, X.Y. Xia, X.M. Luo, Y.T. Deng, S.S. 
He, Y.Y. Mao, X.C. Peng, Y.Q. Weil, Y. Jiang, The effect of chronic stress on 
anti-angiogenesis of sunitinib in colorectal cancer models, 
Psychoneuroendocrinology, 52 (2015) 130-142. 
[118] G.H. Deng, J. Liu, J. Zhang, Y. Wang, X.C. Peng, Y.Q. Wei, Y. Jiang, 
Exogenous norepinephrine attenuates the efficacy of sunitinib in a mouse cancer 
model, J Exp Clin Canc Res, 33 (2014). 
[119] D. Hanahan, L.M. Coussens, Accessories to the crime: functions of cells 
recruited to the tumor microenvironment, Cancer Cell, 21 (2012) 309-322. 
[120] M.G. Morvan, L.L. Lanier, NK cells and cancer: you can teach innate cells 
new tricks, Nat Rev Cancer, 16 (2016) 7-19. 
[121] S. Hadrup, M. Donia, P. Thor Straten, Effector CD4 and CD8 T cells and 
their role in the tumor microenvironment, Cancer Microenviron, 6 (2013) 123-133. 
[122] G.T. Motz, S.P. Santoro, L.P. Wang, T. Garrabrant, R.R. Lastra, I.S. 
Hagemann, P. Lal, M.D. Feldman, F. Benencia, G. Coukos, Tumor endothelium 
159  
  
FasL establishes a selective immune barrier promoting tolerance in tumors, Nat 
Med, 20 (2014) 607-615. 
[123] G.N. Armaiz-Pena, V. Gonzalez-Villasana, A.S. Nagaraja, C. Rodriguez-
Aguayo, N.C. Sadaoui, R.L. Stone, K. Matsuo, H.J. Dalton, R.A. Previs, N.B. 
Jennings, P. Dorniak, J.M. Hansen, J.M. Arevalo, S.W. Cole, S.K. Lutgendorf, 
A.K. Sood, G. Lopez-Berestein, Adrenergic regulation of monocyte chemotactic 
protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma 
growth, Oncotarget, 6 (2015) 4266-4273. 
[124] E.K. Sloan, S.J. Priceman, B.F. Cox, S. Yu, M.A. Pimentel, V. 
Tangkanangnukul, J.M.G. Arevalo, K. Morizono, B.D.W. Karanikolas, L. Wu, A.K. 
Sood, S.W. Cole, The Sympathetic Nervous System Induces a Metastatic Switch 
in Primary Breast Cancer, Cancer Res, 70 (2010) 7042-7052. 
[125] E. Rosenne, L. Sorski, L. Shaashua, E. Neeman, P. Matzner, B. Levi, S. 
Ben-Eliyahu, In vivo suppression of NK cell cytotoxicity by stress and surgery: 
glucocorticoids have a minor role compared to catecholamines and 
prostaglandins, Brain, behavior, and immunity, 37 (2014) 207-219. 
[126] G. Shakhar, S. Ben-Eliyahu, In vivo beta-adrenergic stimulation suppresses 
natural killer activity and compromises resistance to tumor metastasis in rats, 
Journal of immunology, 160 (1998) 3251-3258. 
[127] B. Annabi, M.P. Lachambre, K. Plouffe, R. Moumdjian, R. Beliveau, 
Propranolol adrenergic blockade inhibits human brain endothelial cells 
tubulogenesis and matrix metalloproteinase-9 secretion, Pharmacological 
research, 60 (2009) 438-445. 
160  
  
[128] I. Sardi, L. Giunti, C. Bresci, A.M. Buccoliero, D. Degl'innocenti, S. 
Cardellicchio, G. Baroni, F. Castiglione, M.D. Ros, P. Fiorini, S. Giglio, L. 
Genitori, M. Arico, L. Filippi, Expression of beta-adrenergic receptors in pediatric 
malignant brain tumors, Oncology letters, 5 (2013) 221-225. 
[129] H.P. Nguyen, B.B. Pickrell, T.S. Wright, Beta-Blockers as Therapy for 
Infantile Hemangiomas, Semin Plast Surg, 28 (2014) 87-90. 
[130] S. Madar, I. Goldstein, V. Rotter, 'Cancer associated fibroblasts' - more 
than meets the eye, Trends Mol Med, 19 (2013) 447-453. 
[131] F. Xing, J. Saidou, K. Watabe, Cancer associated fibroblasts (CAFs) in 
tumor microenvironment, Front Biosci, 15 (2010) 166-179. 
[132] A. Ostman, M. Augsten, Cancer-associated fibroblasts and tumor growth - 
bystanders turning into key players, Curr Opin Genet Dev, 19 (2009) 67-73. 
[133] R. Kalluri, The biology and function of fibroblasts in cancer, Nat Rev 
Cancer, 16 (2016) 582-598. 
[134] R. Kalluri, M. Zeisberg, Fibroblasts in cancer, Nature Reviews Cancer, 6 
(2006) 392-401. 
[135] H. Sugimoto, T.M. Mundel, M.W. Kieran, R. Kalluri, Identification of 
fibroblast heterogeneity in the tumor microenvironment, Cancer biology & 
therapy, 5 (2006) 1640-1646. 
[136] S. Kidd, E. Spaeth, K. Watson, J. Burks, H. Lu, A. Klopp, M. Andreeff, F.C. 
Marini, Origins of the tumor microenvironment: quantitative assessment of 
adipose-derived and bone marrow-derived stroma, PloS one, 7 (2012) e30563. 
161  
  
[137] D.C. Radisky, P.A. Kenny, M.J. Bissell, Fibrosis and cancer: Do 
myofibroblasts come also from epithelial cells via EMT?, Journal of cellular 
biochemistry, 101 (2007) 830-839. 
[138] E.M. Zeisberg, S. Potenta, L. Xie, M. Zeisberg, R. Kalluri, Discovery of 
endothelial to mesenchymal transition as a source for carcinoma-associated 
fibroblasts, Cancer Res, 67 (2007) 10123-10128. 
[139] C.S. Leung, T.L. Yeung, K.P. Yip, S. Pradeep, L. Balasubramanian, J. Liu, 
K.K. Wong, L.S. Mangala, G.N. Armaiz-Pena, G. Lopez-Berestein, A.K. Sood, 
M.J. Birrer, S.C. Mok, Calcium-dependent FAK/CREB/TNNC1 signalling 
mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential, 
Nature communications, 5 (2014) 5092. 
[140] Y.A. Zhang, H.J. Tang, J. Cai, T. Zhang, J.F. Guo, D.L. Feng, Z.H. Wang, 
Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma 
metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell 
invasion, Cancer letters, 303 (2011) 47-55. 
[141] N. Erez, M. Truitt, P. Olson, S.T. Arron, D. Hanahan, Cancer-Associated 
Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting 
Inflammation in an NF-kappaB-Dependent Manner, Cancer cell, 17 (2010) 135-
147. 
[142] G.S. Karagiannis, D.F. Schaeffer, C.K.J. Cho, N. Musrap, P. Saraon, I. 
Batruch, A. Grin, B. Mitrovic, R. Kirsch, R.H. Riddell, E.P. Diamandis, Collective 
migration of cancer-associated fibroblasts is enhanced by overexpression of tight 
162  
  
junction-associated proteins daudin-11 and occludin, Mol Oncol, 8 (2014) 178-
195. 
[143] M. Fang, J.P. Yuan, C.W. Peng, Y. Li, Collagen as a double-edged sword 
in tumor progression, Tumor Biol, 35 (2014) 2871-2882. 
[144] T. Li, S. Yi, W. Liu, C. Jia, G. Wang, X. Hua, Y. Tai, Q. Zhang, G. Chen, 
Colorectal carcinoma-derived fibroblasts modulate natural killer cell phenotype 
and antitumor cytotoxicity, Medical oncology, 30 (2013) 663. 
[145] N.N. Lin, P. Wang, D. Zhao, F.J. Zhang, K. Yang, R. Chen, Significance of 
oral cancer-associated fibroblasts in angiogenesis, lymphangiogenesis, and 
tumor invasion in oral squamous cell carcinoma, J Oral Pathol Med, 46 (2017) 
21-30. 
[146] D. Tang, J. Gao, S. Wang, N. Ye, Y. Chong, Y. Huang, J. Wang, B. Li, W. 
Yin, D. Wang, Cancer-associated fibroblasts promote angiogenesis in gastric 
cancer through galectin-1 expression, Tumour biology : the journal of the 
International Society for Oncodevelopmental Biology and Medicine, 37 (2016) 
1889-1899. 
[147] T. Nagasaki, M. Hara, H. Nakanishi, H. Takahashi, M. Sato, H. Takeyama, 
Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour 
angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and 
inhibited tumour-stroma interaction, British journal of cancer, 110 (2014) 469-
478. 
[148] R. Kalluri, The biology and function of exosomes in cancer, J Clin Invest, 
126 (2016) 1208-1215. 
163  
  
[149] Y. Xia, A.L. Schneyer, The biology of activin: recent advances in structure, 
regulation and function, Journal of Endocrinology, 202 (2009) 1-12. 
[150] A.S. Link, F. Zheng, C. Alzheimer, Activin Signaling in the Pathogenesis 
and Therapy of Neuropsychiatric Diseases, Front Mol Neurosci, 7 (2016). 
[151] S. Wildi, J. Kleeff, H. Maruyama, C.A. Maurer, M.W. Buchler, M. Korc, 
Overexpression of activin A in stage IV colorectal cancer, Gut, 49 (2001) 409-
417. 
[152] M. Bashir, S. Damineni, G. Mukherjee, P. Kondaiah, Activin-A signaling 
promotes epithelial–mesenchymal transition, invasion, and metastatic growth of 
breast cancer, Npj Breast Cancer, 1 (2015) 15007. 
[153] J. Hofland, W.M. van Weerden, J. Steenbergen, N.F.J. Dits, G. Jenster, 
F.H. de Jong, Activin A Stimulates AKR1C3 Expression and Growth in Human 
Prostate Cancer, Endocrinology, 153 (2012) 5726-5734. 
[154] M. Basu, R. Bhattacharya, U. Ray, S. Mukhopadhyay, U. Chatterjee, S.S. 
Roy, Invasion of ovarian cancer cells is induced byPITX2-mediated activation of 
TGF-beta and Activin-A, Molecular cancer, 14 (2015). 
[155] M.S. Cho, H.G. Vasquez, R. Rupaimoole, S. Pradeep, S. Wu, B. Zand, 
H.D. Han, C. Rodriguez-Aguayo, J. Bottsford-Miller, J. Huang, T. Miyake, H.J. 
Choi, H.J. Dalton, C. Ivan, K. Baggerly, G. Lopez-Berestein, A.K. Sood, V. 
Afshar-Kharghan, Autocrine effects of tumor-derived complement, Cell reports, 6 
(2014) 1085-1095. 
[156] T.L. Yeung, C.S. Leung, K.K. Wong, G. Samimi, M.S. Thompson, J. Liu, 
T.M. Zaid, S. Ghosh, M.J. Birrer, S.C. Mok, TGF-beta modulates ovarian cancer 
164  
  
invasion by upregulating CAF-derived versican in the tumor microenvironment, 
Cancer Res, 73 (2013) 5016-5028. 
[157] J. Halder, A.A. Kamat, C.N. Landen, L.Y. Han, S.K. Lutgendorf, Y.G. Lin, 
W.M. Merritt, N.B. Jennings, A. Chavez-Reyes, R.L. Coleman, D.M. Gershenson, 
R. Schmandt, S.W. Cole, G. Lopez-Berestein, A.K. Sood, Focal adhesion kinase 
targeting using in vivo short interfering RNA delivery in neutral liposomes for 
ovarian carcinoma therapy, Clin Cancer Res, 12 (2006) 4916-4924. 
[158] C.N. Landen, A. Chavez-Reyes, C. Bucana, R. Schmandt, M.T. Deavers, 
G. Lopez-Berestein, A.K. Sood, Therapeutic EphA2 gene targeting in vivo using 
neutral liposomal small interfering RNA delivery, Cancer Res, 65 (2005) 6910-
6918. 
[159] B. Gyorffy, A. Lanczky, Z. Szallasi, Implementing an online tool for 
genome-wide validation of survival-associated biomarkers in ovarian-cancer 
using microarray data from 1287 patients, Endocrine-related cancer, 19 (2012) 
197-208. 
[160] B.C. Ozdemir, T. Pentcheva-Hoang, J.L. Carstens, X.F. Zheng, C.C. Wu, 
T.R. Simpson, H. Laklai, H. Sugimoto, C. Kahlert, S.V. Novitskiy, A. De Jesus-
Acosta, P. Sharma, P. Heidari, U. Mahmood, L. Chin, H.L. Moses, V.M. Weaver, 
A. Maitra, J.P. Allison, V.S. LeBleu, R. Kalluri, Depletion of Carcinoma-
Associated Fibroblasts and Fibrosis Induces Immunosuppression and 
Accelerates Pancreas Cancer with Reduced Survival (vol 25, pg 719, 2014), 
Cancer cell, 28 (2015) 831-833. 
165  
  
[161] R. Kvetnansky, C.L. Sun, C.R. Lake, N. Thoa, T. Torda, I.J. Kopin, Effect of 
handling and forced immobilization on rat plasma levels of epinephrine, 
norepinephrine, and dopamine-beta-hydroxylase, Endocrinology, 103 (1978) 
1868-1874. 
[162] P. Micke, A. tman, Tumour-stroma interaction: cancer-associated 
fibroblasts as novel targets in anti-cancer therapy?, Lung Cancer, 45 (2004) 
S163-S175. 
[163] Y. Akiyama-Uchida, N. Ashizawa, A. Ohtsuru, S. Seto, T. Tsukazaki, H. 
Kikuchi, S. Yamashita, K. Yano, Norepinephrine enhances fibrosis mediated by 
TGF-beta in cardiac fibroblasts, Hypertension, 40 (2002) 148-154. 
[164] D. Lau, C.P. Bengtson, B. Buchthal, H. Bading, BDNF Reduces Toxic 
Extrasynaptic NMDA Receptor Signaling via Synaptic NMDA Receptors and 
Nuclear-Calcium-Induced Transcription of inhba/Activin A, Cell reports, 12 (2015) 
1353-1366. 
[165] G. Leto, L. Incorvaia, G. Badalamenti, F.M. Tumminello, N. Gebbia, C. 
Flandina, M. Crescimanno, G. Rini, Activin A circulating levels in patients with 
bone metastasis from breast or prostate cancer, Clin Exp Metastasis, 23 (2006) 
117-122. 
[166] K.L. Reader, E. Gold, Activins and activin antagonists in the human ovary 
and ovarian cancer, Molecular and cellular endocrinology, 415 (2015) 126-132. 
[167] H. Kim, J. Watkinson, V. Varadan, D. Anastassiou, Multi-cancer 
computational analysis reveals invasion-associated variant of desmoplastic 
166  
  
reaction involving INHBA, THBS2 and COL11A1, BMC medical genomics, 3 
(2010) 51. 
[168] D.J. Cheon, Y.G. Tong, M.S. Sim, J. Dering, D. Berel, X.J. Cui, J. Lester, 
J.A. Beach, M. Tighiouart, A.E. Walts, B.Y. Karlan, S. Orsulic, A Collagen-
Remodeling Gene Signature Regulated by TGF-beta Signaling Is Associated 
with Metastasis and Poor Survival in Serous Ovarian Cancer, Clinical Cancer 
Research, 20 (2014) 711-723. 
[169] J.L. Chen, K.L. Walton, H. Qian, T.D. Colgan, A. Hagg, M.J. Watt, C.A. 
Harrison, P. Gregorevic, Differential effects of interleukin-6 and activin A in the 
development of cancer-associated cachexia, Cancer Res, (2016). 
[170] Y. Togashi, A. Kogita, H. Sakamoto, H. Hayashi, M. Terashima, M.A. de 
Velasco, K. Sakai, Y. Fujita, S. Tomida, M. Kitano, K. Okuno, M. Kudo, K. Nishio, 
Activin signal promotes cancer progression and is involved in cachexia in a 
subset of pancreatic cancer, Cancer letters, 356 (2015) 819-827. 
[171] A. Loumaye, M. de Barsy, M. Nachit, P. Lause, L. Frateur, A. van Maanen, 
P. Trefois, D. Gruson, J.P. Thissen, Role of Activin A and myostatin in human 
cancer cachexia, The Journal of clinical endocrinology and metabolism, 100 
(2015) 2030-2038. 
 
  
167  
  
7 Vita 
 
Archana Sidalaghatta Nagaraja was born March 13, 1985 in Bangalore, India. 
She is the younger of 2 children of Sukanya T. and Nagaraja S. R., with older 
brother Ajay.  After graduating from Vijaya PU College, Bangalore, India in 2003 
she attended the RV College of Engineering, Bangalore, India.  In May 2007 she 
graduated 4th in class from Visvesvaraya Technological University with a 
Bachelor’s of Engineering in Biotechnology. She then worked at Cerner 
Healthcare Systems in Bangalore, India. She then entered Drexel University in 
September 2008 and joined the laboratory of Dr. Margaret Wheatley in January 
2009. She graduated in September 2010 with her Masters of Science in 
Biomedical Engineering with her thesis on ‘Ultrasound Contrast Agents to deliver 
curcumin to tumor cells’. She then worked at Norris Cotton Cancer Center at 
Dartmouth College in Dr. Alexey Danilov’s lab (Dr. Murray Korc). She then 
entered the The University of Texas MD Anderson Cancer Center UT Health 
Graduate School of Biomedical Sciences in August 2011 and joined the 
laboratory of Dr. Anil Sood in March 2012.   
 
 
168  
